


<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
         xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2025-09-09T14:04:26Z</responseDate>
    <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:12406546" metadataPrefix="pmc">https://pmc.ncbi.nlm.nih.gov/api/oai/v1/mh/</request>
    
    <GetRecord>
        <record>
    <header>
    <identifier>oai:pubmedcentral.nih.gov:12406546</identifier>
    <datestamp>2025-09-04</datestamp>
    
        
        <setSpec>eyevis</setSpec>
        
    
        
        <setSpec>pmc-open</setSpec>
        
    
</header>
    <metadata>
        
        <article xmlns="https://jats.nlm.nih.gov/ns/archiving/1.4/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.4/ https://jats.nlm.nih.gov/archiving/1.4/xsd/JATS-archivearticle1-4.xsd" article-type="research-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eye Vis (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Eye Vis (Lond)</journal-id><journal-id journal-id-type="pmc-domain-id">2830</journal-id><journal-id journal-id-type="pmc-domain">eyevis</journal-id><journal-title-group><journal-title>Eye and Vision</journal-title></journal-title-group><issn pub-type="epub">2326-0254</issn><publisher><publisher-name>BMC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12406546</article-id><article-id pub-id-type="pmcid-ver">PMC12406546.1</article-id><article-id pub-id-type="pmcaid">12406546</article-id><article-id pub-id-type="pmcaiid">12406546</article-id><article-id pub-id-type="pmid">40898311</article-id><article-id pub-id-type="doi">10.1186/s40662-025-00451-3</article-id><article-id pub-id-type="publisher-id">451</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Early retinal changes in type 2 diabetes detected by texture-based OCT analysis: potential approach for subclinical diabetic retinopathy diagnosis</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0423-7959</contrib-id><name name-style="western"><surname>Oliveira</surname><given-names initials="S">Sara</given-names></name><address><email>saraoliveira116@gmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Guimar&#227;es</surname><given-names initials="P">Pedro</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Roque-Rosado</surname><given-names initials="&#xC2;">&#194;ngelo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Campos</surname><given-names initials="EJ">Elisa Juli&#227;o</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Serranho</surname><given-names initials="P">Pedro</given-names></name><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff8">8</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Matafome</surname><given-names initials="P">Paulo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff9">9</xref><xref ref-type="aff" rid="Aff10">10</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Bernardes</surname><given-names initials="R">Rui</given-names></name><address><email>rmbernardes@fmed.uc.pt</email></address><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref><xref ref-type="aff" rid="Aff5">5</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Ambr&#243;sio</surname><given-names initials="AF">Ant&#243;nio Francisco</given-names></name><address><email>afambrosio@fmed.uc.pt</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Faculty of Medicine, </institution><institution>Coimbra Institute for Clinical and Biomedical Research (iCBR), University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Center for Innovative Biomedicine and Biotechnology (CiBB), </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Clinical Academic Center of Coimbra (CACC), </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Faculty of Medicine, </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Department of Chemical Engineering, Chemical Engineering and Renewable Resources for Sustainability (CEReS), </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Center for Neuroscience and Cell Biology (CNC), </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02rv3w387</institution-id><institution-id institution-id-type="GRID">grid.26693.38</institution-id><institution-id institution-id-type="ISNI">0000 0001 2353 7714</institution-id><institution>Department of Sciences and Technology, </institution><institution>Universidade Aberta, </institution></institution-wrap>Lisbon, Portugal </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>Faculty of Medicine, Institute of Physiology, </institution><institution>University of Coimbra, </institution></institution-wrap>Coimbra, Portugal </aff><aff id="Aff10"><label>10</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/04z8k9a98</institution-id><institution-id institution-id-type="GRID">grid.8051.c</institution-id><institution-id institution-id-type="ISNI">0000 0000 9511 4342</institution-id><institution>H&amp;TRC&#8212;Health &amp; Technology Research Center, Polytechnic University of Coimbra, Coimbra Health School (ESTeSC), </institution></institution-wrap>Coimbra, Portugal </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>9</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>12</volume><issue-id pub-id-type="pmc-issue-id">478182</issue-id><elocation-id>36</elocation-id><history><date date-type="received"><day>28</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>8</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>09</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>04</day><month>09</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-09-04 10:25:45.023"><day>04</day><month>09</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="40662_2025_Article_451.pdf"/><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Diabetic retinopathy&#160;(DR) is often diagnosed many years after diabetes onset, highlighting the need for early diagnosis. The current study aimed to assess whether texture analysis of computed optical coherence tomography (OCT) retinal images can identify (very) early retinal changes. We previously reported retinal texture changes in a type 1 diabetes animal model. This study extends this approach to a type 2 diabetes model exhibiting subtler, more gradually developing retinal alterations to further explore its potential for detecting texture changes when DR-related retinal alterations are minor, strengthening its promising value.</p></sec><sec><title>Methods</title><p id="Par2">OCT scans and electroretinograms were acquired at baseline and 4, 8, and 12&#160;weeks after initiating the diabetes induction protocol. Automated OCT segmentation, retinal thickness computation, and texture analysis were performed. Blood-retinal barrier permeability, glial reactivity, neuroinflammation, and nitrosative stress were assessed.</p></sec><sec><title>Results</title><p id="Par3">Retinal texture was affected in the inner plexiform layer and inner/outer photoreceptor segments. At weeks 8 and 12, autocorrelation, cluster prominence, correlation, homogeneity, information measure of correlation II, inverse difference moment normalised, inverse difference normalised, and sum average texture metrics significantly increased/decreased. Importantly, seven of these metrics were also altered in our previous study with type 1 diabetic animals. Type 2 diabetic retinas presented subtle thinning and impaired function, along with a slight reduction in tight junction proteins immunoreactivity, without affecting the blood-retinal barrier.</p></sec><sec><title>Conclusions</title><p id="Par4">The findings from this study indicate that texture analysis can identify subtle retinal changes during early, clinically silent stages of disease, when biological alterations remain minimal. This highlights its potential utility for the early diagnosis of diabetic retinopathy, though further clinical validation is needed.</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s40662-025-00451-3.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Diabetic retinopathy</kwd><kwd>Early biomarkers</kwd><kwd>Optical coherence tomography</kwd><kwd>Texture analysis</kwd><kwd>Type 2 diabetes</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001871</institution-id><institution>Funda&#231;&#227;o para a Ci&#234;ncia e a Tecnologia</institution></institution-wrap></funding-source><award-id>2020.07432.BD</award-id><award-id>UIDB/04539/Base/2020</award-id><award-id>UIDP/04539/Programatico/2020</award-id><award-id>UIDB/04950/Base/2020</award-id><award-id>UIDP/04950/Programatico/2020</award-id><award-id>UIDB/04539/Base/2025</award-id><award-id>UIDP/04539/Programatico/2025</award-id><principal-award-recipient><name name-style="western"><surname>Oliveira</surname><given-names>Sara</given-names></name><name name-style="western"><surname>Bernardes</surname><given-names>Rui</given-names></name><name name-style="western"><surname>Ambr&#243;sio</surname><given-names>Ant&#243;nio Francisco</given-names></name></principal-award-recipient></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100019598</institution-id><institution>Sociedade Portuguesa De Diabetologia</institution></institution-wrap></funding-source><award-id>Bolsa Charneco da Costa - Investiga&#231;&#227;o Fundamental em Diabetologia</award-id><award-id>Bolsas e Pr&#233;mios SPD 2024</award-id><principal-award-recipient><name name-style="western"><surname>Ambr&#243;sio</surname><given-names>Ant&#243;nio Francisco</given-names></name></principal-award-recipient></award-group></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Wenzhou Medical University 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par39">The most prevalent cause of blindness in working-age adults is diabetic retinopathy (DR), a global epidemic with high incidence rates, affecting more than 130 million people worldwide [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. Evidence gathered in recent decades has demonstrated the significant role of neurodegeneration in the early stages of the disease. Accordingly, DR is now widely accepted as a neurovascular complication, affecting both retinal microvasculature and neural cells, accompanied by chronic low-grade neuroinflammation [<xref ref-type="bibr" rid="CR4">4</xref>&#8211;<xref ref-type="bibr" rid="CR7">7</xref>]. Under diabetic conditions, hyperglycaemia-induced oxidative stress and inflammation contribute to the disruption of tight junctions, leading to the impairment of the blood-retinal barrier [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p id="Par40">Despite significant advancements over the past two decades, and the development of several treatment options, patients with DR are often undertreated or do not receive timely intervention until later stages of the disease. In addition, there is a large gap between the diagnosis of diabetes mellitus and the detection of the first clinical signs of DR [<xref ref-type="bibr" rid="CR10">10</xref>]. During this period, the retina undergoes irreversible (molecular and cellular) changes that are undetectable with the clinical resources currently available in clinical practice [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>], including (ultra-widefield) retinal photography, (ultra-widefield) fluorescein angiography, optical coherence tomography (OCT), and OCT angiography. Therefore, finding novel strategies for the detection of subclinical, &#8220;silent&#8221; stages of DR may be important for improving the disease detection and management. This enables timely examination and personalised treatment, thereby contributing to reducing the incidence of visual impairment or blindness.</p><p id="Par41">OCT, which provides non-invasive, high-resolution cross-sectional images of the retina, is commonly used for the diagnosis of retinal diseases [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. In current clinical practice, OCT is used essentially to assess retinal structure and thickness; however, several research groups [<xref ref-type="bibr" rid="CR17">17</xref>&#8211;<xref ref-type="bibr" rid="CR22">22</xref>], including our group [<xref ref-type="bibr" rid="CR23">23</xref>&#8211;<xref ref-type="bibr" rid="CR29">29</xref>], have shown that OCT images convey more in-depth information about the retina&#8217;s status. Our team identified significant differences in retinal texture between a transgenic mouse model of Alzheimer&#8217;s disease and the respective control mice, as well as differences along the disease&#8217;s progression [<xref ref-type="bibr" rid="CR30">30</xref>]. In clinical studies, this approach has also yielded promising results, allowing us to discriminate between Alzheimer&#8217;s disease, Parkinson&#8217;s disease, and healthy controls [<xref ref-type="bibr" rid="CR31">31</xref>]. More recently, we conducted a longitudinal study using an animal model of streptozotocin (STZ)-induced type 1 diabetes with severe hyperglycaemia [<xref ref-type="bibr" rid="CR32">32</xref>]. In this study, a similar texture-based methodology was applied for the first time in the context of diabetes to evaluate the potential of texture analysis in assessing early changes in the diabetic retina. Early after diabetes onset, we identified significant differences between diabetic and control animals in the following retinal texture metrics across all retinal layers: autocorrelation, correlation, homogeneity, information measure of correlation II (IMCII), inverse difference moment normalised (IDN), inverse difference normalised (INN), and sum average. These texture changes were concomitant with structural, functional, molecular, and cellular retinal alterations.</p><p id="Par42">We previously demonstrated the ability to detect retinal texture changes in an animal model of type 1 diabetes, which exhibits severe hyperglycaemia and early development of molecular and cellular retinal alterations. Thus, in this study, the same methodology was applied using an animal model of type 2 diabetes. Here, retinal changes are more subtle and progress more gradually. Accordingly, the present study sought to investigate whether retinal texture is also altered when milder diabetes-induced changes occur in the retina. By exploring texture changes in an animal model with subtler retinal changes, this study explores the potential of our texture-based approach for detecting (very) early retinal alterations, thereby further underscoring the relevance of this strategy and validating its promising value for the early detection of DR, even at &#8220;silent&#8221; stages. As a proof of concept, this longitudinal study used Wistar Han rats (male and female rats) induced by a high-fat diet (HFD) and a low-dose intraperitoneal (IP) injection of STZ (35&#160;mg/kg). To assess whether potential retinal texture changes occur concomitantly, or not, with DR-related biological alterations in the retina, OCT and electroretinography (ERG) acquisitions were performed, along with the evaluation of molecular, cellular, and vascular parameters. The grey-level co-occurrence matrix (GLCM), a statistical method that provides a statistical distribution of grey levels in an image, was used to extract texture metrics from the OCT-derived images of rat retinas.</p><p id="Par43">Animal models are fundamental for providing critical insights into DR pathophysiology, diagnosis, and treatment. Although no single animal model of diabetes precisely recapitulates every aspect of human DR, studies conducted with the animal model employed in this study (HFD/STZ-induced diabetic rats) reported hyperglycaemia, obesity, retinal function abnormalities, decreased retinal thickness, increased acellular capillaries, and decreased number of pericytes [<xref ref-type="bibr" rid="CR33">33</xref>&#8211;<xref ref-type="bibr" rid="CR35">35</xref>]. As texture refers to a complex characterisation of the structural arrangement of image regions and does not possess a (direct) relation with a specific biological process, it is important to clarify whether the potential changes in retinal texture are concomitant, or not, with biological alterations in the retina. Therefore, performing an animal study is indispensable, allowing us to evaluate biological parameters that cannot be assessed in vivo in humans, such as the immunoreactivity of tight junction proteins and the levels of pro-inflammatory mediators in the retina. It also enables the assessment of retinal changes (very) early after diabetes onset, potentially at disease stages that would not be detectable with the diagnostic resources currently used in ophthalmological practice. Accordingly, this study hypothesises that texture analysis holds the potential for detecting retinal changes at subclinical, &#8220;silent&#8221; stages of DR, when the retina is undergoing very subtle and early (molecular and cellular) alterations.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Animal model and ethics</title><p id="Par44">All animal procedures were performed in compliance with the European Community directive guidelines (2010/63/EU) for the use of experimental animals, transposed into Portuguese law in 2013 (Decreto-lei 113/2013). The procedures were approved by the Animal Welfare Committee of the Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra (ORBEA 02/2021), and received further approval from the Dire&#231;&#227;o Geral de Alimenta&#231;&#227;o e Veterin&#225;ria (DGAV &#8211; approval no. 0421/000/000/2021). Additionally, the animal experimentation was conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.</p><p id="Par45">Male and female (10-week-old) Wistar Han rats (Charles River Laboratories, Lyon, France) were housed in certified facilities with a temperature- and humidity-controlled environment, maintained under a 12&#160;h:12&#160;h light&#8211;dark cycle, and with ad libitum access to food and water. The animals were randomly divided into the control and diabetic (T2D) groups. Type 2 diabetes was induced by a HFD containing approximately 40% total fat (Special Diet HF231&#8212;PF4486; Mucedola srl, Settimo Milanese, Italy) for 12&#160;weeks, in combination with a single low-dose STZ injection (35&#160;mg/kg in 10&#160;mM sodium citrate buffer, pH 4.5; IP; after 6&#160;h fasting) in the fourth week after starting the diet (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a). Fasting glycaemia (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>b) and body weight (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>c) were monitored at the beginning of the study, i.e., just before starting the diet (week 0), and after 4, 5, 6, 8, and 12&#160;weeks on HFD. Glycated haemoglobin (HbA1c) was measured at weeks 4 and 12 (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>d), and the oral glucose tolerance test (OGTT; 1.8&#160;mg/kg glucose) was performed at weeks 0 and 12 (the results for week 12 are presented in Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>e).<fig id="Fig1" position="float" orientation="portrait"><label>Fig.&#160;1</label><caption><p>Impact of diabetes on body weight and metabolic parameters. (<bold>a</bold>) Protocol of type 2 diabetes induction. Animals were fed a high-fat diet&#160;(HFD) for 12&#160;weeks, combined with a single low-dose STZ injection (35&#160;mg/kg, IP) in the fourth week after starting the diet. (<bold>b</bold>)&#160;Fasting glycaemia (6&#160;h fasting), (<bold>c</bold>)&#160;body weight, and (<bold>d</bold>)&#160;HbA1c were monitored in diabetic Wistar Han rats (T2D group) and age-matched controls (Control group). (<bold>e</bold>) The OGTT (1.8&#160;g/kg glucose) was performed after 6&#160;h of fasting (only the results obtained after 12&#160;weeks on HFD are presented). Results are presented as mean&#8201;&#177;&#8201;SEM. Statistical analysis was performed using the Mann&#8211;Whitney test. *<italic toggle="yes">P</italic>&#8201;&#8804;&#8201;0.05, **<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001, versus the age-matched Control group. STZ, streptozotocin; IP,&#160;intraperitoneal;&#160;HbA1c, glycated haemoglobin; T2D, type 2 diabetes; OGTT, oral glucose tolerance test; SEM, standard error of the mean</p></caption><graphic id="MO1" position="float" orientation="portrait" xlink:href="40662_2025_451_Fig1_HTML.jpg"/></fig></p></sec><sec id="Sec4"><title>OCT data acquisition</title><p id="Par46">Animals were anesthetised with an IP injection of ketamine (30&#160;mg/kg; Nimatek, Dechra, Northwich, UK) and medetomidine (1&#160;mg/kg; Sedator, Dechra, Northwich, UK) in 0.1&#160;mL saline solution, followed by corneal anaesthesia with oxybuprocaine (4&#160;mg/mL; Anestocil, Edol, Lisbon, Portugal), and full pupil dilation using a topical drop of tropicamide (10&#160;mg/mL; Tropicil Top, Edol, Lisbon, Portugal). To keep the corneal surface moisturised, carmellose sodium (4&#160;mg/0.4&#160;mL; Celluvisc, Allergan, Dublin, Ireland) lubricating eye drops were regularly applied. The retinas from the right eye of control (<italic toggle="yes">N</italic>&#8201;=&#8201;44) and diabetic (<italic toggle="yes">N</italic>&#8201;=&#8201;45) animals were imaged using a Micron IV OCT System (Phoenix Technology Group, Pleasanton, CA, USA) at the baseline (week 0) and after 4, 8, and 12&#160;weeks on HFD. Retinal OCT volumes were acquired consisting of 512 B-scans each (composed of 512 A-scans of 1024 pixels in length), imaged at a predefined retinal region (located above the optic disc, maintaining a horizontal alignment with its centre). The B-scans were saved as non-compressed TIFF image files. All OCT data acquisitions were performed by the same operator. In the molecular and cellular studies, multiple parameters were assessed using retinal samples from the same animals.</p></sec><sec id="Sec5"><title>Automatic retinal segmentation and retinal thickness measurement</title><p id="Par47">The retinal layer segmentation was achieved using a fully convolutional neural network, following a ResNet architecture, as previously described [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>]. A total of six distinct structures (layers and layer aggregates) were segmented: the nerve fiber layer and ganglion cell layer complex (NFL-GCL), the inner plexiform layer (IPL), the inner nuclear layer (INL), the outer plexiform layer (OPL), the outer nuclear layer (ONL), and the inner/outer photoreceptor segments (IS/OS). Volumetric segmentation was determined by combining the 512 segmented B-scans. An expert (author S.O.) evaluated the quality of the segmentation in a masked fashion for both experimental groups. After obtaining the volumetric segmented OCT data, retinal thickness maps were computed for each of the six retinal layers, and the thickness of each retinal layer/layer conjugate, as well as the thickness of the entire retina, were calculated as the distance between the respective segmented boundaries, as reported in our previous work [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec><sec id="Sec6"><title>Texture analysis</title><p id="Par48">For each layer, projection mean-value fundus (MVF) images [<xref ref-type="bibr" rid="CR25">25</xref>] were computed from volume OCT data, as previously described [<xref ref-type="bibr" rid="CR32">32</xref>]. MVF images consist of 2-dimensional (2D) images in which each pixel&#8217;s value is the average of the values of each A-scan between two retinal layer interfaces defining the layer. These allow the projection of the 3-dimensional (3D) OCT data onto a 2D plane, which mimics a fundus photograph capturing only the layer of interest. Texture-related features were extracted from the MVF images using the GLCM statistical method, as described previously [<xref ref-type="bibr" rid="CR32">32</xref>]. The key concept of GLCM lies in analysing the probability of finding a transition from a grey-level A to a grey-level B along an established direction and distance in the image. By computing all possible different transitions at a pre-defined pixel distance and direction, GLCM provides texture information of the image being analysed. Twenty features per layer were computed, namely: the inverse difference moment/energy, contrast/inertia, correlation, angular second moment/uniformity/homogeneity, sum average, sum of squares, sum variance, sum entropy, difference variance, difference entropy, information measure of correlation I (IMCI), IMCII, and entropy, as described by Haralick et al. [<xref ref-type="bibr" rid="CR38">38</xref>]; autocorrelation and maximum probability, as described by Haralick et al. [<xref ref-type="bibr" rid="CR39">39</xref>]; cluster prominence and cluster shade, as described by Conners et al. [<xref ref-type="bibr" rid="CR40">40</xref>]; INN and IDN, as described by Clausi et al. [<xref ref-type="bibr" rid="CR41">41</xref>]; and dissimilarity, as described by Soh et al. [<xref ref-type="bibr" rid="CR42">42</xref>].</p></sec><sec id="Sec7"><title>ERG</title><p id="Par49">Animals were anesthetised as described above, and electroretinograms were recorded at baseline (week 0) and after 4, 8, and 12&#160;weeks on HFD, following the protocol from our previous study [<xref ref-type="bibr" rid="CR32">32</xref>]. In brief, after a dark adaptation overnight, retinal ganglion cell (RGC) function was registered by stimulating both eyes with a 0.000095&#160;cd&#183;s/m<sup>2</sup> light stimulus, following the scotopic threshold response (STR) protocol. The scotopic luminance response was also recorded under scotopic conditions by stimulation with light flashes ranging from 0.0095 to 9.49&#160;cd&#183;s/m<sup>2</sup>, inducing rod activation (a-wave), followed by the subsequent activation of the downstream retinal cells [oscillatory potentials (OPs) and b-wave]. Then, after light adaptation to a 25&#160;cd/m<sup>2</sup> white background for 15&#160;min, the photopic luminance response was recorded in response to a 0.0095 to 9.49&#160;cd&#183;s/m<sup>2</sup> light stimulus. To obtain a more isolated response from cones, the photopic flicker protocol was performed by stimulation with white light flashes (0.95, 3.00, and 9.49&#160;cd&#183;s/m<sup>2</sup>) delivered 10 times at 6.33&#160;Hz. ERGs were recorded using a RETIport System (Roland Consult GmbH, Brandenburg, Germany), and the light stimulation was performed using a Ganzfeld stimulator (Roland Consult GmbH, Brandenburg, Germany), with the data being extracted from the RETIport software (Roland Consult GmbH, Brandenburg, Germany).</p><p id="Par50">Following OCT and ERG recordings, atipamezole (1&#160;mg/kg; Revazol, Dechra, Northwich, UK) was injected intraperitoneally to reverse medetomidine sedation.</p></sec><sec id="Sec8"><title>Immunofluorescence</title><sec id="Sec9"><title>Retinal wholemounts</title><p id="Par51">Animals were anesthetised (2.5% isoflurane in O<sub>2</sub>; IsoFLO, Ecuphar, Oostkamp, Belgium) and euthanised by cervical dislocation. The retinas were then dissected, and the retinal wholemounts were prepared following the procedure previously reported by our group [<xref ref-type="bibr" rid="CR32">32</xref>]. Briefly, after fixation with 4% paraformaldehyde (PFA) for 10&#160;min, the retinal wholemounts were blocked for 1&#160;h with 5% bovine serum albumin (BSA) and incubated for 72&#160;h with antibodies against claudin-5, occludin, and zonula occludens-1 (ZO-1; Table&#160;<xref rid="Tab1" ref-type="table">1</xref>). After washing, the retinas were incubated with the corresponding secondary antibodies (Table&#160;<xref rid="Tab1" ref-type="table">1</xref>) for 24&#160;h, followed by incubation with 1:1000 DAPI (Thermo Fisher Scientific, Waltham, MA, USA), and then mounted with the vitreous side up for visualisation under the LSM 710 Meta confocal laser scanning microscope (Zeiss, Jena, Germany) with a 20&#8201;&#215;&#8201;objective (Plan Achromat 20&#8201;&#215;&#8201;/0.8 M27).
<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table&#160;1</label><caption><p>List of antibodies used for immunofluorescence of retinal wholemounts</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antibody</th><th align="left" colspan="1" rowspan="1">Dilution</th><th align="left" colspan="1" rowspan="1">Company</th><th align="left" colspan="1" rowspan="1">Catalogue number</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Mouse anti-occludin</td><td align="left" colspan="1" rowspan="1">1:100</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">33&#8211;1500</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-claudin-5</td><td align="left" colspan="1" rowspan="1">1:100</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">34&#8211;1600</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-ZO-1</td><td align="left" colspan="1" rowspan="1">1:100</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">40&#8211;2200</td></tr><tr><td align="left" colspan="1" rowspan="1">AlexaFluor 488 goat anti-rabbit</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">A-11008</td></tr><tr><td align="left" colspan="1" rowspan="1">AlexaFluor 568 goat anti-mouse</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">A-11004</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec10"><title>Retinal cryosections</title><p id="Par52">Retinal sections&#160;(14-&#956;m thick) were prepared as described previously [<xref ref-type="bibr" rid="CR32">32</xref>]. Briefly, these were fixed in cold acetone for 10&#160;min, permeabilized for 30&#160;min, and blocked with 10% normal goat serum and 1% BSA before overnight incubation with primary antibodies against Iba1, OX-6/MHC II, glial fibrillary acidic protein (GFAP), vimentin, and nitrotyrosine (at 4&#160;&#176;C; Table&#160;<xref rid="Tab2" ref-type="table">2</xref>). Sections were then washed and incubated with the secondary antibodies (Table&#160;<xref rid="Tab2" ref-type="table">2</xref>) and 1:5000 DAPI for 1&#160;h at room temperature. For image analysis, the images were captured with a fluorescence microscope (Axio Observer.Z1, Zeiss, Jena, Germany) using a 20&#8201;&#215;&#8201;objective (Plan Achromat 20&#8201;&#215;&#8201;/0.8 M27). Representative Z-stack images were acquired with a 20&#8201;&#215;&#8201;objective (Plan Achromat 20&#8201;&#215;&#8201;/0.8 M27) on a confocal microscope (Zeiss LSM 710, Zeiss, Jena, Germany).
<table-wrap id="Tab2" position="float" orientation="portrait"><label>Table&#160;2</label><caption><p>List of antibodies used for immunofluorescence of retinal sections</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antibody</th><th align="left" colspan="1" rowspan="1">Dilution</th><th align="left" colspan="1" rowspan="1">Company</th><th align="left" colspan="1" rowspan="1">Catalogue number</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-nitrotyrosine</td><td align="left" colspan="1" rowspan="1">1:100</td><td align="left" colspan="1" rowspan="1">Millipore</td><td align="left" colspan="1" rowspan="1">06-284</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-Iba1</td><td align="left" colspan="1" rowspan="1">1:1000</td><td align="left" colspan="1" rowspan="1">Wako</td><td align="left" colspan="1" rowspan="1">019-19741</td></tr><tr><td align="left" colspan="1" rowspan="1">Mouse anti-MHC Class II (OX-6)</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Bio-Rad</td><td align="left" colspan="1" rowspan="1">MCA46A647</td></tr><tr><td align="left" colspan="1" rowspan="1">Chicken anti-GFAP</td><td align="left" colspan="1" rowspan="1">1:500</td><td align="left" colspan="1" rowspan="1">Millipore</td><td align="left" colspan="1" rowspan="1">AB5541</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-vimentin</td><td align="left" colspan="1" rowspan="1">1:500</td><td align="left" colspan="1" rowspan="1">Abcam</td><td align="left" colspan="1" rowspan="1">ab92547</td></tr><tr><td align="left" colspan="1" rowspan="1">AlexaFluor 488 goat anti-rabbit</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">A-11008</td></tr><tr><td align="left" colspan="1" rowspan="1">AlexaFluor 568 goat anti-chicken</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">A-11041</td></tr><tr><td align="left" colspan="1" rowspan="1">AlexaFluor 568 goat anti-mouse</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">A-11004</td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec11"><title>Evans blue assay</title><p id="Par53">Blood-retinal barrier permeability was qualitatively assessed using the Evans blue assay, following our group&#8217;s previously published protocol [<xref ref-type="bibr" rid="CR32">32</xref>]. Animals were anesthetised with an IP injection of ketamine (75&#160;mg/kg; Nimatek, Dechra, Northwich, UK) and medetomidine (1&#160;mg/kg; Sedator, Dechra, Northwich, UK). After filtration (pore size, 0.2&#160;&#956;m), Evans blue (100&#160;mg/kg in PBS; Sigma-Aldrich, St. Louis, MO, USA) was injected via the tail vein, and the animals were kept on a warm pad for 2&#160;h. The eyes were enucleated and fixed with 2% PFA for 2&#160;h, after which the retinas were dissected and mounted with the vitreous side up for visualisation under the LSM 710 Meta confocal laser scanning microscope (Zeiss, Jena, Germany) with a 20&#8201;&#215;&#8201;objective (Plan Achromat 20&#8201;&#215;&#8201;/0.8 M27).</p></sec><sec id="Sec12"><title>Western blotting</title><p id="Par54">Retinal lysates were prepared, and Western blot was performed as described previously [<xref ref-type="bibr" rid="CR32">32</xref>]. In brief, equal amounts of protein (30&#160;&#181;g) were loaded onto 6%&#8211;12% polyacrylamide gels, separated through sodium dodecyl sulphate&#8211;polyacrylamide gel electrophoresis (SDS-PAGE), and transferred to polyvinylidene fluoride membranes (Millipore, Billerica, MA, USA). After blocking for 2&#160;h at room temperature, membranes were incubated overnight with claudin-5, occludin, ZO-1, interleukin-1 beta (IL-1&#946;), and tumour necrosis factor (TNF) primary antibodies (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>), followed by 2&#160;h incubation with the corresponding secondary antibodies (Table&#160;<xref rid="Tab3" ref-type="table">3</xref>). Immunoblots were imaged on the ImageQuant&#8482; LAS 500 (GE Healthcare, Chicago, IL, USA), and band intensity was quantified using ImageQuant 5.0 software (Molecular Dynamics, Sunnyvale, CA, USA).
<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table&#160;3</label><caption><p>List of antibodies used for Western blotting</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Antibody</th><th align="left" colspan="1" rowspan="1">Dilution</th><th align="left" colspan="1" rowspan="1">Company</th><th align="left" colspan="1" rowspan="1">Catalogue number</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-occludin</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">71-1500</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-claudin-5</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">34-1600</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-ZO-1</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">40-2200</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-IL-1&#946;</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Abcam</td><td align="left" colspan="1" rowspan="1">ab9722</td></tr><tr><td align="left" colspan="1" rowspan="1">Rabbit anti-TNF</td><td align="left" colspan="1" rowspan="1">1:200</td><td align="left" colspan="1" rowspan="1">Abcam</td><td align="left" colspan="1" rowspan="1">ab66579</td></tr><tr><td align="left" colspan="1" rowspan="1">Goat anti-calnexin</td><td align="left" colspan="1" rowspan="1">1:1000</td><td align="left" colspan="1" rowspan="1">Sicgen</td><td align="left" colspan="1" rowspan="1">AB0041-500</td></tr><tr><td align="left" colspan="1" rowspan="1">HRP goat anti-rabbit</td><td align="left" colspan="1" rowspan="1">1:10,000</td><td align="left" colspan="1" rowspan="1">Bio-Rad</td><td align="left" colspan="1" rowspan="1">1706515</td></tr><tr><td align="left" colspan="1" rowspan="1">HRP rabbit anti-goat</td><td align="left" colspan="1" rowspan="1">1:10,000</td><td align="left" colspan="1" rowspan="1">Invitrogen</td><td align="left" colspan="1" rowspan="1">61-1620</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec13"><title>Enzyme-linked immunosorbent assay</title><p id="Par55">For tissue preparation, one retina from each eye was homogenised in lysis buffer [20&#160;mM imidazole HCl, 100&#160;mM KCl, 1&#160;mM MgCl<sub>2</sub>, 1% (vol./vol.) Triton X-100, 1&#160;mM EGTA, 1&#160;mM EDTA, 10&#160;mM NaF, and 1&#160;mM Na<sub>3</sub>VO<sub>4</sub> (activated), supplemented with complete mini protease inhibitor cocktail tablets]. Then, following the manufacturer&#8217;s instructions, the protein levels of IL-1&#946; and TNF were assessed in retinal homogenates using the rat IL-1&#946; and TNF enzyme-linked immunosorbent assay (ELISA) kits (#RAB0478 and #RAB0480; Sigma-Aldrich, St. Louis, MO, USA), respectively.</p></sec><sec id="Sec14"><title>Statistical analysis</title><p id="Par56">ANCOVA tests were performed to assess differences between groups and each individual time point of the study (after 4, 8, and 12&#160;weeks on HFD) after adjusting for the baseline (week 0), which was used as a quantitative covariate. Additionally, the results from retinal thickness, metabolic parameters, Western blot, and immunofluorescence were analysed using the Student&#8217;s t-test, or the Mann&#8211;Whitney test, if data were not normally distributed, which was assessed using the Shapiro&#8211;Wilk test. SPSS software (version 27; IBM Corp., Armonk, NY, USA) was used to perform the statistical analysis, where we considered a statistical significance of 5%. Results are presented as mean&#8201;&#177;&#8201;standard error of the mean (SEM), except for the graphs of the retinal texture, in which the results are expressed by box plots showing the median (horizontal line), 25th and 75th percentiles (box), and minimum and maximum (error bars). The results of the retinal thickness were calculated as the percentage of the baseline and are presented as mean&#8201;&#177;&#8201;SEM.</p></sec></sec><sec id="Sec15"><title>Results</title><sec id="Sec16"><title>Type 2 diabetes triggers early texture changes in specific retinal layers</title><p id="Par57">We previously identified significant texture changes in retinal OCT images obtained from an animal model of type 1 diabetes, early after diabetes onset, suggesting that texture analysis offers a promising approach for the early detection of DR [<xref ref-type="bibr" rid="CR32">32</xref>]. Accordingly, the main goal of the present work is to evaluate the potential of this texture analysis-based approach in HFD/STZ-induced type 2 diabetic animals, in which molecular and cellular changes are subtler and progress more slowly. It is important to highlight that animals on HFD for 8 and 12&#160;weeks were injected with STZ at week 4 (Fig.&#160;<xref rid="Fig1" ref-type="fig">1</xref>a). After 8 and 12&#160;weeks on HFD, significant changes were found in several GLCM-based texture metrics in specific retinal layers, namely in the IPL and IS/OS, compared to control animals. More specifically, the IPL presented a significant decrease in the texture metrics autocorrelation (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a1) and sum average (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a8); conversely, there was an increase in the texture metrics cluster prominence (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a2), correlation (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a3), homogeneity (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a4), IMCII (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a5), and INN (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a7), compared to control animals. A significant increase in the IDN texture parameter was also observed, but only at week 12 (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>a6). The same texture parameters were affected in the retinal layer IS/OS (Fig.&#160;<xref rid="Fig2" ref-type="fig">2</xref>b1&#8211;8). However, in contrast to the IPL, all these parameters significantly decreased after 8 and 12&#160;weeks on HFD, compared with controls. After 4&#160;weeks on HFD, no changes were observed in any of these texture metrics. The mean values&#8201;&#177;&#8201;SEM for each parameter assessed and the corresponding significance <italic toggle="yes">P</italic> values are provided in Supplementary Table S1.<fig id="Fig2" position="float" orientation="portrait"><label>Fig.&#160;2</label><caption><p>Diabetes triggers (very) early texture changes extracted from retinal OCT images. Diabetic Wistar Han rats (induced by a 12-week HFD with STZ injection at week 4; 35&#160;mg/kg, IP; T2D group; <italic toggle="yes">N</italic>&#8201;=&#8201;45), presented changes in retinal texture, compared with age-matched controls (Control group; <italic toggle="yes">N</italic>&#8201;=&#8201;44), in the following GLCM-based textural parameters in the inner plexiform layer (IPL) and inner/outer photoreceptor segments (IS/OS), respectively: (<bold>a1</bold>, <bold>b1</bold>)&#160;autocorrelation; (<bold>a2</bold>, <bold>b2</bold>)&#160;cluster prominence; (<bold>a3</bold>, <bold>b3</bold>)&#160;correlation; (<bold>a4</bold>, <bold>b4</bold>)&#160;homogeneity; (<bold>a5</bold>, <bold>b5</bold>)&#160;information measure of correlation II (IMCII); (<bold>a6</bold>, <bold>b6</bold>)&#160;inverse difference moment normalised (IDN); (<bold>a7</bold>, <bold>b7</bold>)&#160;inverse difference normalised (INN); (<bold>a8</bold>, <bold>b8</bold>)&#160;sum average. The results are expressed by box plots showing the median (horizontal line), 25th and 75th percentiles (box), and minimum and maximum (error bars) for the IPL and IS/OS in each texture parameter. Statistical analysis was performed using the ANCOVA test, considering the baseline values (week 0) as a quantitative covariate. *<italic toggle="yes">P</italic>&#8201;&#8804;&#8201;0.05, **<italic toggle="yes"> P</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes"> P</italic>&#8201;&lt;&#8201;0.001, versus the age-matched Control group. OCT, optical coherence tomography; STZ, streptozotocin; IP,&#160;intraperitoneal;&#160;T2D, type 2 diabetes; GLCM, grey-level co-occurrence matrix; HFD, high-fat diet</p></caption><graphic id="MO2" position="float" orientation="portrait" xlink:href="40662_2025_451_Fig2_HTML.jpg"/></fig></p></sec><sec id="Sec17"><title>Type 2 diabetes significantly impacts retinal thickness</title><p id="Par58">The effect of diabetes on retinal thickness was assessed on the segmented retinal layers (NFL-GCL, IPL, INL, OPL, ONL, and IS/OS) as well as on the total retina (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>a&#8211;h). Almost all retinal layers were significantly thinner in diabetic animals after 8 and 12&#160;weeks on HFD, compared to controls, as follows: IPL [Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 97.5%&#8201;&#177;&#8201;0.4% and 96.9%&#8201;&#177;&#8201;0.3% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 95.4%&#8201;&#177;&#8201;0.5% (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and 95.2%&#8201;&#177;&#8201;0.5% (<italic toggle="yes">P</italic>&#8201;=&#8201;0.004) at weeks 8 and 12, respectively; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>b], INL (Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 92.2%&#8201;&#177;&#8201;0.4% and 89.4%&#8201;&#177;&#8201;0.4% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 86.3%&#8201;&#177;&#8201;0.6% and 86.0%&#8201;&#177;&#8201;0.5% at weeks 8 and 12, respectively, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>c), OPL [Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 98.4%&#8201;&#177;&#8201;0.3% and 98.6%&#8201;&#177;&#8201;0.3% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 96.7%&#8201;&#177;&#8201;0.4% (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002) and 97.4%&#8201;&#177;&#8201;0.4% (<italic toggle="yes">P</italic>&#8201;=&#8201;0.013) at weeks 8 and 12, respectively; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>d], ONL [Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 96.1%&#8201;&#177;&#8201;0.3% and 94.3%&#8201;&#177;&#8201;0.3% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 93.5%&#8201;&#177;&#8201;0.4% (<italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001) and 93.0%&#8201;&#177;&#8201;0.3% (<italic toggle="yes">P</italic>&#8201;=&#8201;0.008) at weeks 8 and 12, respectively; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>e], and IS/OS (Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 102.1%&#8201;&#177;&#8201;0.7% and 100.3%&#8201;&#177;&#8201;0.8% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 90.5%&#8201;&#177;&#8201;0.8% and 91.5%&#8201;&#177;&#8201;0.8% at weeks 8 and 12, respectively, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001; Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>f). Retinal thinning was also observed in the T2D group after 4&#160;weeks on HFD, namely in the INL and ONL [Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 95.5%&#8201;&#177;&#8201;0.4% and 97.9%&#8201;&#177;&#8201;0.2% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 93.7%&#8201;&#177;&#8201;0.4% (<italic toggle="yes">P</italic>&#8201;=&#8201;0.001) and 96.9%&#8201;&#177;&#8201;0.3% (<italic toggle="yes">P</italic>&#8201;=&#8201;0.010), respectively] and in the photoreceptor segments (Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 101.9%&#8201;&#177;&#8201;0.9% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 96.1%&#8201;&#177;&#8201;0.7%, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001). As a result, a significant decrease in the total retinal thickness (Fig.&#160;<xref rid="Fig3" ref-type="fig">3</xref>g) was observed in diabetic rats after 4, 8, and 12&#160;weeks on HFD (Control: <italic toggle="yes">N</italic>&#8201;=&#8201;44, 99.1%&#8201;&#177;&#8201;0.3%, 98.0%&#8201;&#177;&#8201;0.3%, and 96.5%&#8201;&#177;&#8201;0.3% vs. T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;45, 97.3&#8201;&#177;&#8201;0.3%, 93.3&#8201;&#177;&#8201;0.4%, and 93.2&#8201;&#177;&#8201;0.3% at weeks 4, 8, and 12, respectively, <italic toggle="yes">P</italic>&#8201;&lt;&#8201;0.001), compared to age-matched controls.<fig id="Fig3" position="float" orientation="portrait"><label>Fig.&#160;3</label><caption><p>Diabetes induces retinal thinning. Diabetic Wistar Han rats (induced by a 12-week HFD with STZ injection at week 4; 35&#160;mg/kg, IP; T2D group; <italic toggle="yes">N</italic>&#8201;=&#8201;45) presented a decrease in retinal thickness compared to age-matched controls (Control group; <italic toggle="yes">N</italic>&#8201;=&#8201;44). The retinal thickness of control and diabetic rats was assessed in the following retinal layers: (<bold>a</bold>) nerve fibre layer and ganglion cell layer complex (NFL-GCL); (<bold>b</bold>)&#160;inner plexiform layer (IPL); (<bold>c</bold>)&#160;inner nuclear layer (INL); (<bold>d</bold>)&#160;outer plexiform layer (OPL); (<bold>e</bold>)&#160;outer nuclear layer (ONL); (<bold>f</bold>)&#160;inner/outer photoreceptor segments (IS/OS). (<bold>g</bold>) Total retinal thickness was calculated as the sum of the six retinal layers. (<bold>h</bold>) Representative OCT images for Control and T2D groups after 12&#160;weeks on HFD. Scale bar: 100&#160;&#956;m. Results were calculated as the percentage of the baseline and are presented as mean&#8201;&#177;&#8201;SEM. Statistical analysis was performed using the Student&#8217;s <italic toggle="yes">t</italic>-test, or the Mann&#8211;Whitney test, if data were not normally distributed. *<italic toggle="yes">P</italic>&#8201;&#8804;&#8201;0.05, **<italic toggle="yes"> P</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes"> P</italic>&#8201;&lt;&#8201;0.001, versus the age-matched Control group. HFD, high-fat diet; STZ, streptozotocin; IP,&#160;intraperitoneal;&#160;T2D, type 2 diabetes; SEM, standard error of the mean</p></caption><graphic id="MO3" position="float" orientation="portrait" xlink:href="40662_2025_451_Fig3_HTML.jpg"/></fig></p></sec><sec id="Sec18"><title>Type 2 diabetes increases the latency of the OPs under scotopic conditions</title><p id="Par59">Electroretinograms, which measure the electrical response of the retina to light flashes, were performed to investigate the effect of diabetes on the retinal physiology. At all experimental time points (after 4, 8, and 12&#160;weeks on HFD), the retinal function of diabetic animals was mostly unaffected under both scotopic (Supplementary Figure S1) and photopic conditions (Supplementary Figure S2), compared with control animals, except for the scotopic OPs (Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>a&#8211;q). In OP1, increased latencies were registered after 12&#160;weeks on HFD, in response to a 3&#160;cd&#183;s/m<sup>2</sup> light stimulus (Control: 14.6&#8201;&#177;&#8201;0.1&#160;ms vs. T2D: 15.0&#8201;&#177;&#8201;0.1&#160;ms, <italic toggle="yes">P</italic>&#8201;=&#8201;0.017; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>c), whereas, in OP2 and OP3, this effect was observed earlier (after 8&#160;weeks on HFD) in response to 3&#160;cd&#183;s/m<sup>2</sup> [Control: <italic toggle="yes">N</italic>&#8201;=&#8201;24, 20.5&#8201;&#177;&#8201;0.2&#160;ms and 28.2&#8201;&#177;&#8201;0.3&#160;ms vs<italic toggle="yes">.</italic> T2D: <italic toggle="yes">N</italic>&#8201;=&#8201;21, 21.3&#8201;&#177;&#8201;0.2&#160;ms (<italic toggle="yes">P</italic>&#8201;=&#8201;0.002) and 29.2&#8201;&#177;&#8201;0.3&#160;ms (<italic toggle="yes">P</italic>&#8201;=&#8201;0.021) in OP2 and OP3, respectively; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>g and k] and 9.49&#160;cd&#183;s/m<sup>2</sup> light stimuli [Control: <italic toggle="yes">N</italic>&#8201;=&#8201;24, 20.4&#8201;&#177;&#8201;0.2&#160;ms and 28.1&#8201;&#177;&#8201;0.3&#160;ms vs<italic toggle="yes">.</italic> T2D:<italic toggle="yes"> N</italic>&#8201;=&#8201;21, 21.1&#8201;&#177;&#8201;0.2&#160;ms (<italic toggle="yes">P</italic>&#8201;=&#8201;0.009) and 29.1&#8201;&#177;&#8201;0.3&#160;ms (<italic toggle="yes">P</italic>&#8201;=&#8201;0.011) in OP2 and OP3, respectively; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>h and l], and remained significant until week 12. Regarding the OP4, a delayed response was observed after 8&#160;weeks on HFD under both light stimuli analysed (3&#160;cd&#183;s/m<sup>2</sup> and 9.49&#160;cd&#183;s/m<sup>2</sup>; Fig.&#160;<xref rid="Fig4" ref-type="fig">4</xref>o and p, respectively), although this effect was lost at week 12.<fig id="Fig4" position="float" orientation="portrait"><label>Fig.&#160;4</label><caption><p>Impact of diabetes on oscillatory potentials (OPs). The response of the scotopic OPs was delayed in diabetic Wistar Han rats (induced by a 12-week HFD with STZ injection at week 4; 35&#160;mg/kg, IP; T2D group; <italic toggle="yes">N</italic>&#8201;=&#8201;21), compared to age-matched controls (Control group; <italic toggle="yes">N</italic>&#8201;=&#8201;24). OP1, OP2, OP3, and OP4 amplitudes were recorded in response to (<bold>a</bold>, <bold>e</bold>, <bold>i</bold>, and <bold>m</bold>, respectively) 3&#160;cd&#183;s/m<sup>2</sup> and (<bold>b</bold>, <bold>f</bold>, <bold>j</bold>, and <bold>n</bold>, respectively) 9.49&#160;cd&#183;s/m<sup>2</sup> light stimuli. Latencies of OP1, OP2, OP3, and OP4 were recorded in response to (<bold>c</bold>, <bold>g</bold>, <bold>k</bold>, and <bold>o</bold>, respectively) 3&#160;cd&#183;s/m<sup>2</sup> and (<bold>d</bold>, <bold>h</bold>, <bold>l</bold>, and <bold>p</bold>, respectively) 9.49&#160;cd&#183;s/m<sup>2</sup> light stimuli. (<bold>q</bold>) Representative traces of OPs of control and diabetic animals, recorded after 12&#160;weeks on HFD, were obtained after applying an Off-line digital filter (low frequency cutoff of 60&#160;Hz). Results are presented as mean&#8201;&#177;&#8201;SEM. Statistical analysis was performed using the ANCOVA test, considering the baseline values (week 0) as a quantitative covariate. *<italic toggle="yes">P</italic>&#8201;&#8804;&#8201;0.05, **<italic toggle="yes"> P</italic>&#8201;&lt;&#8201;0.01, ***<italic toggle="yes"> P</italic>&#8201;&lt;&#8201;0.001, versus the age-matched Control group. HFD, high-fat diet; STZ, streptozotocin; IP,&#160;intraperitoneal;&#160;T2D, type 2 diabetes</p></caption><graphic id="MO4" position="float" orientation="portrait" xlink:href="40662_2025_451_Fig4_HTML.jpg"/></fig></p></sec><sec id="Sec19"><title>Type 2 diabetes induces mild changes in tight junction protein expression without causing vascular leakage</title><p id="Par60">The impact of diabetes on the tight junction proteins claudin-5, occludin, and ZO-1 was assessed in retinal wholemounts and homogenates by immunofluorescence and Western blot, respectively. After 8&#160;weeks on HFD, a qualitative analysis of the retinal wholemounts revealed a slight decrease in claudin-5 immunoreactivity in the superficial capillary plexus (SCP) in diabetic rats, which persisted until week 12, compared with controls (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>a). A subtle decrease in occludin immunoreactivity was also observed after 12&#160;weeks on HFD, both in the SCP and in the deep capillary plexus (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>b). Regarding ZO-1 immunoreactivity, no changes were observed in retinal wholemounts from diabetic animals (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>c). No differences were detected in the protein levels of tight junction proteins in retinal homogenates by Western blot (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>e&#8211;g). Despite subtle changes detected in the immunoreactivity of tight junction proteins in retinal wholemounts from diabetic animals, no vascular leakage was observed, as assessed by Evans Blue assay (Fig.&#160;<xref rid="Fig5" ref-type="fig">5</xref>d).<fig id="Fig5" position="float" orientation="portrait"><label>Fig.&#160;5</label><caption><p>Diabetes triggers slight immunoreactive changes in tight junction proteins, without changes in retinal vascular permeability. Diabetic Wistar Han rats (induced by a 12-week HFD with STZ injection at week 4; 35&#160;mg/kg, IP; T2D group) presented a slight decrease in claudin-5 immunoreactivity after 8&#160;weeks on HFD, as well as in occludin and claudin-5 immunostaining at week 12, as assessed in retinal wholemounts. However, no differences were found in its protein levels in retinal extracts, assessed by Western blot, compared to age-matched controls (Control group). No vascular leakage was detected in diabetic animals, as assessed by the Evans blue assay. Representative images of retinal wholemounts immunostained for (<bold>a</bold>)&#160;claudin-5, (<bold>b</bold>)&#160;occludin, and (<bold>c</bold>)&#160;ZO-1. (<bold>d</bold>) Representative images showing Evans blue fluorescence in the retina. (<bold>e</bold>)&#160;Claudin-5, (<bold>f</bold>)&#160;occludin, and (<bold>g</bold>)&#160;ZO-1 protein levels assessed by Western blot, normalised to the loading control (calnexin), and expressed as percentage of the respective control. Representative images of protein immunoreactive bands are presented above the graphs, with the respective loading control (calnexin). Data are presented as mean&#8201;&#177;&#8201;SEM. Statistical analysis was performed using the Student&#8217;s <italic toggle="yes">t</italic>-test, or the Mann&#8211;Whitney test, if data were not normally distributed. HFD, high-fat diet; STZ, streptozotocin; IP,&#160;intraperitoneal;&#160;T2D, type 2 diabetes; ZO-1, zonula occludens-1</p></caption><graphic id="MO5" position="float" orientation="portrait" xlink:href="40662_2025_451_Fig5_HTML.jpg"/></fig></p></sec><sec id="Sec20"><title>Type 2 diabetes does not induce nitrosative stress and glial reactivity in the retina</title><p id="Par61">Diabetic retinas were assessed for nitrosative stress by immunofluorescence in retinal cryosections. Additionally, to evaluate the effects of type 2 diabetes on neuroinflammation, M&#252;ller cell and microglia reactivity was also assessed by immunofluorescence in retinal cryosections, along with the assessment of IL-1&#946; and TNF protein levels in retinal homogenates by Western blot and ELISA. In diabetic animals, there were no signs of nitrosative stress, as evidenced by no significant differences in nitrotyrosine immunoreactivity in the retina (Supplementary Figure S3a and S3d), compared with controls. Further, there was no evidence of neuroinflammation, since no changes were found in Iba1<sup>+</sup> cell density (microglia/macrophages; Supplementary Figure S3b and S3e), and in the morphology and reactivity of M&#252;ller cells (Supplementary Figure S3c and S3f), when compared with controls. In addition, the protein content of IL-1&#946; (Supplementary Figure S3g and S3h) and TNF (Supplementary Figure S3i and S3j) remained unaffected under diabetic conditions.</p></sec></sec><sec id="Sec21"><title>Discussion</title><p id="Par62">Significant advances in ophthalmic imaging techniques have been made in recent decades, particularly with the introduction of OCT technology, including OCT angiography more recently, but also with significant improvements in more traditional techniques, such as ultra-widefield retinal photography and ultra-widefield fluorescein angiography. Despite remarkable progress, DR is regarded as a &#8220;silent&#8221; disease because it is usually diagnosed many years after diabetes onset, at disease stages when significant biological changes have already occurred in the retina. Indeed, molecular and cellular changes linked to neurovascular and physiological dysfunction are known to precede the development of the first clinical signs of DR [<xref ref-type="bibr" rid="CR11">11</xref>&#8211;<xref ref-type="bibr" rid="CR14">14</xref>]. Since the diagnostic methods currently available in clinical practice are unable to detect such early (molecular and cellular) changes, an earlier diagnosis of DR remains a major challenge in diabetes research, and therefore there is an urgent need for novel strategies.</p><p id="Par63">In a previous study by our group, significant changes in retinal texture were observed between diabetic and control animals in several retinal texture metrics, across all retinal layers, with differences also noted over the course of the disease [<xref ref-type="bibr" rid="CR32">32</xref>]. These changes were concomitant with structural, functional, molecular, and cellular alterations in the retina. In this study, the same methodological approach was applied to HFD/STZ-induced type 2 diabetic animals, which exhibit milder and more gradually progressing DR-related retinal alterations. The current study aimed to evaluate potential retinal texture changes (very) early after disease onset and assess whether these changes were concomitant with retinal alterations typically linked to the pathophysiology of DR, including structural (layer thickness) and functional (ERG) changes, as well as molecular, cellular, and vascular alterations.</p><p id="Par64">Performing an animal study was fundamental because it enabled us to assess retinal texture (very) early after diabetes onset, potentially at stages in which clinical resources currently available in clinical practice cannot detect any retinal biological alterations. Furthermore, animal models enable the assessment of DR-related molecular and cellular parameters in the retina, which cannot be evaluated in vivo in humans. Considering that current diagnostic resources used in the clinical management of DR can readily detect advanced disease stages, it is important to highlight that our texture analysis approach is not particularly relevant for those cases. Moreover, this study does not replace a clinical study, as human data is fundamental for corroborating the current findings and, most importantly, to validate this texture-based approach. Evidence from animal models is crucial to establish a proof of concept and to provide a solid rationale for subsequent clinical research.</p><p id="Par65">While animal models are invaluable for studying diabetes-induced (very) early retinal changes and the underlying molecular and cellular alterations, they do not fully replicate the full spectrum of retinal abnormalities observed in patients with DR. Furthermore, it remains unclear whether the early retinal alterations detected in diabetic animals represent early disease features and progress to long-term retinal damage. It is also uncertain whether these changes are directly related to diabetes or influenced by other factors. Unlike human patients, animal models typically do not receive any treatment targeting diabetes-related metabolic control, which may limit clinical translation. Nonetheless, as noted above, clinical studies remain mandatory to confirm and validate these findings. Given the strong correlation between HbA1c levels and DR [<xref ref-type="bibr" rid="CR43">43</xref>], another limitation of this study arises from the low HbA1c levels detected in animals treated with HFD and STZ. Nonetheless, it is important to note that HbA1c levels in diabetic animals were statistically different from those in controls. Furthermore, fasting blood glucose levels were markedly elevated in the diabetic group, strongly highlighting the hyperglycaemic condition.</p><p id="Par66">Diabetes induced significant differences in several texture parameters (autocorrelation, cluster prominence, correlation, homogeneity, IMCII, IDN, INN, and sum average), but only in the IPL and IS/OS. While seven of these metrics were changed in all retinal layers in our previous studies using an animal model of type 1 diabetes [<xref ref-type="bibr" rid="CR32">32</xref>], here, only two retinal layers presented significant differences in retinal texture. This likely represents an earlier disease stage, also considering that molecular and cellular changes in this type 2 diabetes model are less pronounced and progress more slowly compared to the type 1 diabetes model. The IPL is indeed recognised as one of the retinal layers primarily affected in type 2 diabetic patients without clinical signals of DR [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>], whereas the same is not true for the IS/OS layer. Although scientific evidence suggests that the outer retina appears to be less affected than the inner retina in the early stages of the disease [<xref ref-type="bibr" rid="CR46">46</xref>], the presence of subtle texture changes in the IS/OS indicates that changes in this layer are already occurring. This could somehow reflect subtle biological alterations that have so far been undetectable, suggesting that retinal texture may eventually have the potential to help unmask retinal diseases. Nonetheless, the results gathered in this study reveal that our methodology can identify significant retinal texture changes between diabetic and control animals (very) early after diabetes onset.</p><p id="Par67">Although OCT images offer valuable anatomical information about the retina, evaluating retinal thickness is not sufficient for identifying a specific retinal disease, because retinal thickness is known to be impaired in several eye conditions. In this study, early after the STZ administration (after 8 and 12&#160;weeks on HFD, with STZ injection at week 4), subtle but significant thinning of almost all retinal layers (apart from the NFL-GCL) and of the total retina was detected. It is important to note that many animals (44 control and 45 diabetic animals) and an automated segmentation method were used, which strongly increase the reliability of the retinal thickness results. Surprisingly, animals fed with HFD for 4&#160;weeks already presented a significant decrease in retinal thickness compared to controls. Despite no changes in fasting glucose, this suggests that a higher caloric intake affects the retina. In sum, the findings in this study suggest that diabetic retinas develop retinal thinning early in the course of the disease, which can eventually corroborate the early changes observed in the texture metrics.</p><p id="Par68">Clinical research studies with diabetic patients without DR suggest that the most prominent changes in the ERG response occur in the inner retina, most specifically in the OP responses [<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref>], which was also corroborated in pre-clinical studies [<xref ref-type="bibr" rid="CR50">50</xref>&#8211;<xref ref-type="bibr" rid="CR52">52</xref>]. In this study, diabetic animals presented increased latencies in the scotopic OPs, which is in accordance with the previous observations. Additional significant changes were observed in the ERG recordings, including a decrease in OPs amplitude, although they were sporadic and inconsistent. Thus, the results of the current study provide evidence of early and very low-grade retinal dysfunction by showing that diabetic retinas develop impaired retinal function (very) early after diabetes onset.</p><p id="Par69">Numerous studies have proposed that both neurovascular damage and chronic low-grade inflammation in the retina are clearly involved in the pathophysiology of DR [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR53">53</xref>], and the scientific community working in the field has been very supportive of this hypothesis. As such, in this study, several parameters related to neuronal, glial, and vascular retinal cells were assessed, as well as changes related to neuroinflammation. While no differences were found in neuroinflammatory and glial reactivity markers, minimal vascular-level changes were noted (subtle decrease in tight junction proteins immunoreactivity). However, these changes did not induce any physiologically relevant effect on vascular permeability. Indeed, given that type 2 diabetic animals presented only minor retinal biological changes at the time points assessed in this study, the breakdown of the blood-retinal barrier would not be expected.</p><p id="Par70">In summary, at the time points assessed in this study (after 4, 8, and 12 weeks on HFD), type 2 diabetes induced only minor retinal alterations in structural, functional, molecular, and cellular parameters commonly associated with DR. Nonetheless, these conditions&#8212;a state in which the effects of diabetes on the retina were still minimal&#8212;are precisely the optimal circumstances for investigating whether retinal texture could provide information about minor retinal changes at (very) early stages of the disease. Such findings may ultimately prove useful and translatable after validation in clinical studies. Although a direct association between changes in retinal texture and a specific biological process in the retina cannot be established, the full spectrum of molecular and cellular alterations in the diabetic retina may trigger structural rearrangements in the tissue. In addition, alterations to retinal composition caused by early HFD/STZ-induced changes may result in changes in the refractive index of the retina, leading to differences in the OCT signal that can be detected by texture analysis. Altogether, these alterations can lead to changes in retinal texture that may then serve as indicators of the underlying pathogenic processes and reflect aspects of the disease&#8217;s pathogenesis.</p><p id="Par71">The texture analysis conveys multivariate data on the spatial distribution of image intensity, providing information on subtle structural differences of the distinct retinal layers. As mentioned before, using an animal model of type 1 diabetes, we recently demonstrated that our texture-based methodology is able to spot differences in the retina under diabetic conditions early after diabetes induction [<xref ref-type="bibr" rid="CR32">32</xref>]. In this study, type 2 diabetic animals displayed even subtler retinal biological changes than those we previously observed in type 1 diabetic rats, and yet our methodology consistently discriminated retinal texture between diabetic and control animals. Therefore, the present study significantly strengthens the promising value of this texture-based approach for the early detection of DR. Importantly, seven texture metrics were consistently altered in both experimental models, revealing the coherence of texture results and lending considerable robustness to our texture-based approach.</p></sec><sec id="Sec22"><title>Conclusions</title><p id="Par72">In conclusion, this study strongly supports the potential of texture analysis in providing powerful quantitative information on the retinal status and clearly evidences the ability to identify changes in (very) early stages of the disease, even when very minimal biological changes are occurring in the retina. Further research on this topic, particularly in human subjects, could enable earlier diagnosis of DR, significantly enhancing the management and prognosis of this vision-threatening disease.</p></sec><sec id="Sec23" sec-type="supplementary-material"><title>Supplementary Information</title><p>
<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xlink:href="40662_2025_451_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Additional file 1.</p></caption></media></supplementary-material></p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>2D</term><def><p id="Par5">2-Dimensional</p></def></def-item><def-item><term>BSA</term><def><p id="Par6">Bovine serum albumin</p></def></def-item><def-item><term>DR</term><def><p id="Par7">Diabetic retinopathy</p></def></def-item><def-item><term>IDN</term><def><p id="Par8">Inverse difference moment normalised</p></def></def-item><def-item><term>ERG</term><def><p id="Par9">Electroretinography</p></def></def-item><def-item><term>ELISA</term><def><p id="Par10">Enzyme-linked immunosorbent assay</p></def></def-item><def-item><term>GFAP</term><def><p id="Par11">Glial fibrillary acidic protein</p></def></def-item><def-item><term>HbA1c</term><def><p id="Par12">Glycated haemoglobin</p></def></def-item><def-item><term>GLCM</term><def><p id="Par13">Grey-level co-occurrence matrix</p></def></def-item><def-item><term>HFD</term><def><p id="Par14">High-fat diet</p></def></def-item><def-item><term>IMCI</term><def><p id="Par15">Information measure of correlation I</p></def></def-item><def-item><term>IMCII</term><def><p id="Par16">Information measure of correlation II</p></def></def-item><def-item><term>INL</term><def><p id="Par17">Inner nuclear layer</p></def></def-item><def-item><term>IPL</term><def><p id="Par18">Inner plexiform layer</p></def></def-item><def-item><term>IS/OS</term><def><p id="Par19">Inner/outer photoreceptor segments</p></def></def-item><def-item><term>IL-1&#946;</term><def><p id="Par20">Interleukin-1 beta</p></def></def-item><def-item><term>IP</term><def><p id="Par21">Intraperitoneal</p></def></def-item><def-item><term>INN</term><def><p id="Par22">Inverse difference normalised</p></def></def-item><def-item><term>NFL-GCL</term><def><p id="Par23">Nerve fibre layer and ganglion cell layer complex</p></def></def-item><def-item><term>OCT</term><def><p id="Par24">Optical coherence tomography</p></def></def-item><def-item><term>OGTT</term><def><p id="Par25">Oral glucose tolerance test</p></def></def-item><def-item><term>OP</term><def><p id="Par26">Oscillatory potential</p></def></def-item><def-item><term>ONL</term><def><p id="Par27">Outer nuclear layer</p></def></def-item><def-item><term>OPL</term><def><p id="Par28">Outer plexiform layer</p></def></def-item><def-item><term>PFA</term><def><p id="Par29">Paraformaldehyde</p></def></def-item><def-item><term>MVF</term><def><p id="Par30">Mean-value fundus</p></def></def-item><def-item><term>RGC</term><def><p id="Par31">Retinal ganglion cell</p></def></def-item><def-item><term>SCP</term><def><p id="Par32">Superficial capillary plexus</p></def></def-item><def-item><term>SDS-PAGE</term><def><p id="Par33">Sodium dodecyl sulphate&#8211;polyacrylamide gel electrophoresis</p></def></def-item><def-item><term>SEM</term><def><p id="Par34">Standard error of the mean</p></def></def-item><def-item><term>STR</term><def><p id="Par35">Scotopic threshold response</p></def></def-item><def-item><term>STZ</term><def><p id="Par36">Streptozotocin</p></def></def-item><def-item><term>TNF</term><def><p id="Par37">Tumour necrosis factor</p></def></def-item><def-item><term>ZO-1</term><def><p id="Par38">Zonula occludens-1</p></def></def-item></def-list></glossary><fn-group><fn><p>Rui Bernardes and Ant&#243;nio Francisco Ambr&#243;sio contributed equally to this work and are considered co-senior authors.</p></fn></fn-group><ack><title>Acknowledgements</title><p>The authors thank Dr. Jo&#227;o Martins from the Coimbra Institute for Biomedical Imaging and Translational Research (CIBIT), Institute for Nuclear Sciences Applied to Health (ICNAS), Coimbra, for his support in analysing the ERG data, providing a script for faster data analysis.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Study conception: AFA, RB, and PS; Study design: AFA, RB, and PM; Data collection and analyses: SO, PG, ARR, and&#160;EJC; Interpretation of data: SO, PG, PS, PM, RB,&#160;and AFA; Drafting the manuscript: SO; Critically revising the manuscript for intellectual content: PG, ARR, EJC, PS, PM, RB, and&#160;AFA. All authors have read and approved the final version of the manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This study was supported by the Foundation for Science and Technology, Portugal: 2020.07432.BD, PEst UIDB/04539/Base/2020 and UIDP/04539/Programatico/2020, PEst UIDB/04950/Base/2020 and UIDP/04950/Programatico/2020 and PEst UIDB/04539/Base/2025 and UIDP/04539/Program&#225;tico/2025. This study was also supported by the Sociedade Portuguesa de Diabetologia (SPD), Portugal: Bolsa Charneco da Costa&#8212;Investiga&#231;&#227;o Fundamental em Diabetologia, Bolsas e Pr&#233;mios SPD 2024.</p></notes><notes notes-type="data-availability"><title>Availability of data and materials</title><p>All data generated or analysed during this study are included in this published article and its supplementary information files.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par73">All animal procedures were performed in compliance with the European Community directive guidelines (2010/63/EU) for the use of experimental animals, transposed into Portuguese law in 2013 (Decreto-lei 113/2013). The procedures were approved by the Animal Welfare Committee of the Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine, University of Coimbra (ORBEA 02/2021), and received further approval from the Dire&#231;&#227;o Geral de Alimenta&#231;&#227;o e Veterin&#225;ria (DGAV&#8211;approval no. 0421/000/000/2021). Additionally, animal experimentation was conducted in accordance with the Association for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in Ophthalmic and Vision Research.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par74">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par75">The authors declare that they have no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kropp</surname><given-names>M</given-names></name><name name-style="western"><surname>Golubnitschaja</surname><given-names>O</given-names></name><name name-style="western"><surname>Mazurakova</surname><given-names>A</given-names></name><name name-style="western"><surname>Koklesova</surname><given-names>L</given-names></name><name name-style="western"><surname>Sargheini</surname><given-names>N</given-names></name><name name-style="western"><surname>Vo</surname><given-names>TKS</given-names></name><etal/></person-group><article-title>Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation</article-title><source>EPMA J</source><year>2023</year><volume>14</volume><issue>1</issue><fpage>21</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">36866156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13167-023-00314-8</pub-id><pub-id pub-id-type="pmcid">PMC9971534</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TKS, et al. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation. EPMA J. 2023;14(1):21&#8211;42.<pub-id pub-id-type="pmid">36866156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s13167-023-00314-8</pub-id><pub-id pub-id-type="pmcid">PMC9971534</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wong</surname><given-names>TY</given-names></name><name name-style="western"><surname>Tan</surname><given-names>TE</given-names></name></person-group><article-title>The diabetic retinopathy &#8220;pandemic&#8221; and evolving global strategies: the 2023 friedenwald lecture</article-title><source>Invest Ophthalmol Vis Sci</source><year>2023</year><volume>64</volume><issue>15</issue><fpage>47</fpage><pub-id pub-id-type="pmid">38153754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.64.15.47</pub-id><pub-id pub-id-type="pmcid">PMC10756246</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Wong TY, Tan TE. The diabetic retinopathy &#8220;pandemic&#8221; and evolving global strategies: the 2023 friedenwald lecture. Invest Ophthalmol Vis Sci. 2023;64(15):47.<pub-id pub-id-type="pmid">38153754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.64.15.47</pub-id><pub-id pub-id-type="pmcid">PMC10756246</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Tham</surname><given-names>YC</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chee</surname><given-names>ML</given-names></name><name name-style="western"><surname>Rim</surname><given-names>TH</given-names></name><name name-style="western"><surname>Cheung</surname><given-names>N</given-names></name><etal/></person-group><article-title>Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis</article-title><source>Ophthalmology</source><year>2021</year><volume>128</volume><issue>11</issue><fpage>1580</fpage><lpage>1591</lpage><pub-id pub-id-type="pmid">33940045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2021.04.027</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Teo ZL, Tham YC, Yu M, Chee ML, Rim TH, Cheung N, et al. Global prevalence of diabetic retinopathy and projection of burden through 2045: systematic review and meta-analysis. Ophthalmology. 2021;128(11):1580&#8211;91.<pub-id pub-id-type="pmid">33940045</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ophtha.2021.04.027</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sinclair</surname><given-names>SH</given-names></name><name name-style="western"><surname>Schwartz</surname><given-names>SS</given-names></name></person-group><article-title>Diabetic retinopathy-an underdiagnosed and undertreated inflammatory, neuro-vascular complication of diabetes</article-title><source>Front Endocrinol (Lausanne)</source><year>2019</year><volume>10</volume><fpage>843</fpage><pub-id pub-id-type="pmid">31920963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2019.00843</pub-id><pub-id pub-id-type="pmcid">PMC6923675</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Sinclair SH, Schwartz SS. Diabetic retinopathy-an underdiagnosed and undertreated inflammatory, neuro-vascular complication of diabetes. Front Endocrinol (Lausanne). 2019;10:843.<pub-id pub-id-type="pmid">31920963</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fendo.2019.00843</pub-id><pub-id pub-id-type="pmcid">PMC6923675</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bianco</surname><given-names>L</given-names></name><name name-style="western"><surname>Arrigo</surname><given-names>A</given-names></name><name name-style="western"><surname>Aragona</surname><given-names>E</given-names></name><name name-style="western"><surname>Antropoli</surname><given-names>A</given-names></name><name name-style="western"><surname>Berni</surname><given-names>A</given-names></name><name name-style="western"><surname>Saladino</surname><given-names>A</given-names></name><etal/></person-group><article-title>Neuroinflammation and neurodegeneration in diabetic retinopathy</article-title><source>Front Aging Neurosci</source><year>2022</year><volume>14</volume><fpage>937999</fpage><pub-id pub-id-type="pmid">36051309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.937999</pub-id><pub-id pub-id-type="pmcid">PMC9424735</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Bianco L, Arrigo A, Aragona E, Antropoli A, Berni A, Saladino A, et al. Neuroinflammation and neurodegeneration in diabetic retinopathy. Front Aging Neurosci. 2022;14:937999.<pub-id pub-id-type="pmid">36051309</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2022.937999</pub-id><pub-id pub-id-type="pmcid">PMC9424735</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sim&#243;</surname><given-names>R</given-names></name><name name-style="western"><surname>Sim&#243;-Servat</surname><given-names>O</given-names></name><name name-style="western"><surname>Bogdanov</surname><given-names>P</given-names></name><name name-style="western"><surname>Hern&#225;ndez</surname><given-names>C</given-names></name></person-group><article-title>Diabetic retinopathy: role of neurodegeneration and therapeutic perspectives</article-title><source>Asia-Pacific J Ophthalmol</source><year>2022</year><volume>11</volume><issue>2</issue><fpage>160</fpage><lpage>167</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/APO.0000000000000510</pub-id><pub-id pub-id-type="pmid">35533335</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Sim&#243; R, Sim&#243;-Servat O, Bogdanov P, Hern&#225;ndez C. Diabetic retinopathy: role of neurodegeneration and therapeutic perspectives. Asia-Pacific J Ophthalmol. 2022;11(2):160&#8211;7.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/APO.0000000000000510</pub-id><pub-id pub-id-type="pmid">35533335</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Solomon</surname><given-names>SD</given-names></name><name name-style="western"><surname>Chew</surname><given-names>E</given-names></name><name name-style="western"><surname>Duh</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Sobrin</surname><given-names>L</given-names></name><name name-style="western"><surname>Sun</surname><given-names>JK</given-names></name><name name-style="western"><surname>VanderBeek</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Diabetic retinopathy: a position statement by the American Diabetes Association</article-title><source>Diabetes Care</source><year>2017</year><volume>40</volume><issue>3</issue><fpage>412</fpage><lpage>418</lpage><pub-id pub-id-type="pmid">28223445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc16-2641</pub-id><pub-id pub-id-type="pmcid">PMC5402875</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Solomon SD, Chew E, Duh EJ, Sobrin L, Sun JK, VanderBeek BL, et al. Diabetic retinopathy: a position statement by the American Diabetes Association. Diabetes Care. 2017;40(3):412&#8211;8.<pub-id pub-id-type="pmid">28223445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/dc16-2641</pub-id><pub-id pub-id-type="pmcid">PMC5402875</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rudraraju</surname><given-names>M</given-names></name><name name-style="western"><surname>Narayanan</surname><given-names>SP</given-names></name><name name-style="western"><surname>Somanath</surname><given-names>PR</given-names></name></person-group><article-title>Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy</article-title><source>Pharmacol Res</source><year>2020</year><volume>161</volume><fpage>105115</fpage><pub-id pub-id-type="pmid">32750417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2020.105115</pub-id><pub-id pub-id-type="pmcid">PMC7755666</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Rudraraju M, Narayanan SP, Somanath PR. Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy. Pharmacol Res. 2020;161:105115.<pub-id pub-id-type="pmid">32750417</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.phrs.2020.105115</pub-id><pub-id pub-id-type="pmcid">PMC7755666</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santiago</surname><given-names>AR</given-names></name><name name-style="western"><surname>Boia</surname><given-names>R</given-names></name><name name-style="western"><surname>Aires</surname><given-names>ID</given-names></name><name name-style="western"><surname>Ambr&#243;sio</surname><given-names>AF</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>R</given-names></name></person-group><article-title>Sweet stress: coping with vascular dysfunction in diabetic retinopathy</article-title><source>Front Physiol</source><year>2018</year><volume>9</volume><fpage>820</fpage><pub-id pub-id-type="pmid">30057551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2018.00820</pub-id><pub-id pub-id-type="pmcid">PMC6053590</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Santiago AR, Boia R, Aires ID, Ambr&#243;sio AF, Fernandes R. Sweet stress: coping with vascular dysfunction in diabetic retinopathy. Front Physiol. 2018;9:820.<pub-id pub-id-type="pmid">30057551</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphys.2018.00820</pub-id><pub-id pub-id-type="pmcid">PMC6053590</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>HN</given-names></name><name name-style="western"><surname>Moon</surname><given-names>MK</given-names></name><name name-style="western"><surname>Koo</surname><given-names>BK</given-names></name></person-group><article-title>Prevalence of diabetic retinopathy in undiagnosed diabetic patients: a nationwide population-based study</article-title><source>Diabetes Metab J</source><year>2022</year><volume>46</volume><issue>4</issue><fpage>620</fpage><lpage>629</lpage><pub-id pub-id-type="pmid">35193173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4093/dmj.2021.0099</pub-id><pub-id pub-id-type="pmcid">PMC9353559</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Jang HN, Moon MK, Koo BK. Prevalence of diabetic retinopathy in undiagnosed diabetic patients: a nationwide population-based study. Diabetes Metab J. 2022;46(4):620&#8211;9.<pub-id pub-id-type="pmid">35193173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4093/dmj.2021.0099</pub-id><pub-id pub-id-type="pmcid">PMC9353559</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Asefzadeh</surname><given-names>B</given-names></name><name name-style="western"><surname>Fisch</surname><given-names>BM</given-names></name><name name-style="western"><surname>Parenteau</surname><given-names>CE</given-names></name><name name-style="western"><surname>Cavallerano</surname><given-names>AA</given-names></name></person-group><article-title>Macular thickness and systemic markers for diabetes in individuals with no or mild diabetic retinopathy</article-title><source>Clin Exp Ophthalmol</source><year>2008</year><volume>36</volume><issue>5</issue><fpage>455</fpage><lpage>463</lpage><pub-id pub-id-type="pmid">18925914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1442-9071.2008.01769.x</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Asefzadeh B, Fisch BM, Parenteau CE, Cavallerano AA. Macular thickness and systemic markers for diabetes in individuals with no or mild diabetic retinopathy. Clin Exp Ophthalmol. 2008;36(5):455&#8211;63.<pub-id pub-id-type="pmid">18925914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1442-9071.2008.01769.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chhablani</surname><given-names>J</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Goud</surname><given-names>A</given-names></name><name name-style="western"><surname>Peguda</surname><given-names>HK</given-names></name><name name-style="western"><surname>Rao</surname><given-names>HL</given-names></name><name name-style="western"><surname>Begum</surname><given-names>VU</given-names></name><etal/></person-group><article-title>Neurodegeneration in type 2 diabetes: evidence from spectral-domain optical coherence tomography</article-title><source>Invest Ophthalmol Vis Sci</source><year>2015</year><volume>56</volume><issue>11</issue><fpage>6333</fpage><lpage>6338</lpage><pub-id pub-id-type="pmid">26436886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.15-17334</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Chhablani J, Sharma A, Goud A, Peguda HK, Rao HL, Begum VU, et al. Neurodegeneration in type 2 diabetes: evidence from spectral-domain optical coherence tomography. Invest Ophthalmol Vis Sci. 2015;56(11):6333&#8211;8.<pub-id pub-id-type="pmid">26436886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.15-17334</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>El-Fayoumi</surname><given-names>D</given-names></name><name name-style="western"><surname>BadrEldine</surname><given-names>NM</given-names></name><name name-style="western"><surname>Esmael</surname><given-names>AF</given-names></name><name name-style="western"><surname>Ghalwash</surname><given-names>D</given-names></name><name name-style="western"><surname>Soliman</surname><given-names>HM</given-names></name></person-group><article-title>Retinal nerve fiber layer and ganglion cell complex thicknesses are reduced in children with type 1 diabetes with no evidence of vascular retinopathy</article-title><source>Invest Ophthalmol Vis Sci</source><year>2016</year><volume>57</volume><issue>13</issue><fpage>5355</fpage><lpage>5360</lpage><pub-id pub-id-type="pmid">27737458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.16-19988</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">El-Fayoumi D, BadrEldine NM, Esmael AF, Ghalwash D, Soliman HM. Retinal nerve fiber layer and ganglion cell complex thicknesses are reduced in children with type 1 diabetes with no evidence of vascular retinopathy. Invest Ophthalmol Vis Sci. 2016;57(13):5355&#8211;60.<pub-id pub-id-type="pmid">27737458</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.16-19988</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>van Dijk</surname><given-names>HW</given-names></name><name name-style="western"><surname>Verbraak</surname><given-names>FD</given-names></name><name name-style="western"><surname>Kok</surname><given-names>PH</given-names></name><name name-style="western"><surname>Garvin</surname><given-names>MK</given-names></name><name name-style="western"><surname>Sonka</surname><given-names>M</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K</given-names></name><etal/></person-group><article-title>Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><issue>7</issue><fpage>3660</fpage><lpage>3665</lpage><pub-id pub-id-type="pmid">20130282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.09-5041</pub-id><pub-id pub-id-type="pmcid">PMC2904016</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">van Dijk HW, Verbraak FD, Kok PH, Garvin MK, Sonka M, Lee K, et al. Decreased retinal ganglion cell layer thickness in patients with type 1 diabetes. Invest Ophthalmol Vis Sci. 2010;51(7):3660&#8211;5.<pub-id pub-id-type="pmid">20130282</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.09-5041</pub-id><pub-id pub-id-type="pmcid">PMC2904016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Popescu</surname><given-names>DP</given-names></name><name name-style="western"><surname>Choo-Smith</surname><given-names>LP</given-names></name><name name-style="western"><surname>Flueraru</surname><given-names>C</given-names></name><name name-style="western"><surname>Mao</surname><given-names>Y</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S</given-names></name><name name-style="western"><surname>Disano</surname><given-names>J</given-names></name><etal/></person-group><article-title>Optical coherence tomography: fundamental principles, instrumental designs and biomedical applications</article-title><source>Biophys Rev</source><year>2011</year><volume>3</volume><issue>3</issue><fpage>155</fpage><pub-id pub-id-type="pmid">28510064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12551-011-0054-7</pub-id><pub-id pub-id-type="pmcid">PMC5418377</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Popescu DP, Choo-Smith LP, Flueraru C, Mao Y, Chang S, Disano J, et al. Optical coherence tomography: fundamental principles, instrumental designs and biomedical applications. Biophys Rev. 2011;3(3):155.<pub-id pub-id-type="pmid">28510064</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12551-011-0054-7</pub-id><pub-id pub-id-type="pmcid">PMC5418377</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fujimoto</surname><given-names>JG</given-names></name></person-group><article-title>Optical coherence tomography for ultrahigh resolution in vivo imaging</article-title><source>Nat Biotechnol</source><year>2003</year><volume>21</volume><issue>11</issue><fpage>1361</fpage><lpage>1367</lpage><pub-id pub-id-type="pmid">14595364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt892</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Fujimoto JG. Optical coherence tomography for ultrahigh resolution in vivo imaging. Nat Biotechnol. 2003;21(11):1361&#8211;7.<pub-id pub-id-type="pmid">14595364</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nbt892</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ruggeri</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsechpenakis</surname><given-names>G</given-names></name><name name-style="western"><surname>Jiao</surname><given-names>S</given-names></name><name name-style="western"><surname>Jockovich</surname><given-names>ME</given-names></name><name name-style="western"><surname>Cebulla</surname><given-names>C</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>E</given-names></name><etal/></person-group><article-title>Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography</article-title><source>Opt Express</source><year>2009</year><volume>17</volume><issue>5</issue><fpage>4074</fpage><lpage>4083</lpage><pub-id pub-id-type="pmid">19259247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1364/oe.17.004074</pub-id><pub-id pub-id-type="pmcid">PMC2718719</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Ruggeri M, Tsechpenakis G, Jiao S, Jockovich ME, Cebulla C, Hernandez E, et al. Retinal tumor imaging and volume quantification in mouse model using spectral-domain optical coherence tomography. Opt Express. 2009;17(5):4074&#8211;83.<pub-id pub-id-type="pmid">19259247</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1364/oe.17.004074</pub-id><pub-id pub-id-type="pmcid">PMC2718719</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Venhuizen</surname><given-names>FG</given-names></name><name name-style="western"><surname>van Ginneken</surname><given-names>B</given-names></name><name name-style="western"><surname>van Asten</surname><given-names>F</given-names></name><name name-style="western"><surname>van Grinsven</surname><given-names>MJJP</given-names></name><name name-style="western"><surname>Fauser</surname><given-names>S</given-names></name><name name-style="western"><surname>Hoyng</surname><given-names>CB</given-names></name><etal/></person-group><article-title>Automated staging of age-related macular degeneration using optical coherence tomography</article-title><source>Invest Ophthalmol Vis Sci</source><year>2017</year><volume>58</volume><issue>4</issue><fpage>2318</fpage><lpage>2328</lpage><pub-id pub-id-type="pmid">28437528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.16-20541</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Venhuizen FG, van Ginneken B, van Asten F, van Grinsven MJJP, Fauser S, Hoyng CB, et al. Automated staging of age-related macular degeneration using optical coherence tomography. Invest Ophthalmol Vis Sci. 2017;58(4):2318&#8211;28.<pub-id pub-id-type="pmid">28437528</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.16-20541</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>HW</given-names></name><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name><name name-style="western"><surname>Woung</surname><given-names>LC</given-names></name><name name-style="western"><surname>Lo</surname><given-names>CM</given-names></name></person-group><article-title>A novel machine learning algorithm to automatically predict visual outcomes in intravitreal ranibizumab-treated patients with diabetic macular edema</article-title><source>J Clin Med</source><year>2018</year><volume>7</volume><issue>12</issue><fpage>475</fpage><pub-id pub-id-type="pmid">30477203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm7120475</pub-id><pub-id pub-id-type="pmcid">PMC6306861</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Chen SC, Chiu HW, Chen CC, Woung LC, Lo CM. A novel machine learning algorithm to automatically predict visual outcomes in intravitreal ranibizumab-treated patients with diabetic macular edema. J Clin Med. 2018;7(12):475.<pub-id pub-id-type="pmid">30477203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm7120475</pub-id><pub-id pub-id-type="pmcid">PMC6306861</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>De Fauw</surname><given-names>J</given-names></name><name name-style="western"><surname>Ledsam</surname><given-names>JR</given-names></name><name name-style="western"><surname>Romera-Paredes</surname><given-names>B</given-names></name><name name-style="western"><surname>Nikolov</surname><given-names>S</given-names></name><name name-style="western"><surname>Tomasev</surname><given-names>N</given-names></name><name name-style="western"><surname>Blackwell</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinically applicable deep learning for diagnosis and referral in retinal disease</article-title><source>Nat Med</source><year>2018</year><volume>24</volume><issue>9</issue><fpage>1342</fpage><lpage>1350</lpage><pub-id pub-id-type="pmid">30104768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0107-6</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">De Fauw J, Ledsam JR, Romera-Paredes B, Nikolov S, Tomasev N, Blackwell S, et al. Clinically applicable deep learning for diagnosis and referral in retinal disease. Nat Med. 2018;24(9):1342&#8211;50.<pub-id pub-id-type="pmid">30104768</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0107-6</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yazdanpanah</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamarneh</surname><given-names>G</given-names></name><name name-style="western"><surname>Smith</surname><given-names>BR</given-names></name><name name-style="western"><surname>Sarunic</surname><given-names>MV</given-names></name></person-group><article-title>Segmentation of intra-retinal layers from optical coherence tomography images using an active contour approach</article-title><source>IEEE Trans Med Imaging</source><year>2011</year><volume>30</volume><issue>2</issue><fpage>484</fpage><lpage>496</lpage><pub-id pub-id-type="pmid">20952331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2010.2087390</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Yazdanpanah A, Hamarneh G, Smith BR, Sarunic MV. Segmentation of intra-retinal layers from optical coherence tomography images using an active contour approach. IEEE Trans Med Imaging. 2011;30(2):484&#8211;96.<pub-id pub-id-type="pmid">20952331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2010.2087390</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seebock</surname><given-names>P</given-names></name><name name-style="western"><surname>Waldstein</surname><given-names>SM</given-names></name><name name-style="western"><surname>Klimscha</surname><given-names>S</given-names></name><name name-style="western"><surname>Bogunovic</surname><given-names>H</given-names></name><name name-style="western"><surname>Schlegl</surname><given-names>T</given-names></name><name name-style="western"><surname>Gerendas</surname><given-names>BS</given-names></name><etal/></person-group><article-title>Unsupervised identification of disease marker candidates in retinal OCT imaging data</article-title><source>IEEE Trans Med Imaging</source><year>2019</year><volume>38</volume><issue>4</issue><fpage>1037</fpage><lpage>1047</lpage><pub-id pub-id-type="pmid">30346281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2018.2877080</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Seebock P, Waldstein SM, Klimscha S, Bogunovic H, Schlegl T, Gerendas BS, et al. Unsupervised identification of disease marker candidates in retinal OCT imaging data. IEEE Trans Med Imaging. 2019;38(4):1037&#8211;47.<pub-id pub-id-type="pmid">30346281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/TMI.2018.2877080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardes</surname><given-names>R</given-names></name><name name-style="western"><surname>Santos</surname><given-names>T</given-names></name><name name-style="western"><surname>Serranho</surname><given-names>P</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>C</given-names></name><name name-style="western"><surname>Cunha-Vaz</surname><given-names>J</given-names></name></person-group><article-title>Noninvasive evaluation of retinal leakage using optical coherence tomography</article-title><source>Ophthalmologica</source><year>2011</year><volume>226</volume><issue>2</issue><fpage>29</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">21508651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000326268</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Bernardes R, Santos T, Serranho P, Lobo C, Cunha-Vaz J. Noninvasive evaluation of retinal leakage using optical coherence tomography. Ophthalmologica. 2011;226(2):29&#8211;36.<pub-id pub-id-type="pmid">21508651</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1159/000326268</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guimar&#227;es</surname><given-names>P</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>P</given-names></name><name name-style="western"><surname>Celorico</surname><given-names>D</given-names></name><name name-style="western"><surname>Serranho</surname><given-names>P</given-names></name><name name-style="western"><surname>Bernardes</surname><given-names>R</given-names></name></person-group><article-title>Three-dimensional segmentation and reconstruction of the retinal vasculature from spectral-domain optical coherence tomography</article-title><source>J Biomed Opt</source><year>2015</year><volume>20</volume><issue>1</issue><fpage>16006</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1117/1.JBO.20.1.016006</pub-id><pub-id pub-id-type="pmid">25565582</pub-id></element-citation><mixed-citation id="mc-CR24" publication-type="journal">Guimar&#227;es P, Rodrigues P, Celorico D, Serranho P, Bernardes R. Three-dimensional segmentation and reconstruction of the retinal vasculature from spectral-domain optical coherence tomography. J Biomed Opt. 2015;20(1):16006.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1117/1.JBO.20.1.016006</pub-id><pub-id pub-id-type="pmid">25565582</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guimar&#227;es</surname><given-names>P</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>P</given-names></name><name name-style="western"><surname>Lobo</surname><given-names>C</given-names></name><name name-style="western"><surname>Leal</surname><given-names>S</given-names></name><name name-style="western"><surname>Figueira</surname><given-names>J</given-names></name><name name-style="western"><surname>Serranho</surname><given-names>P</given-names></name><etal/></person-group><article-title>Ocular fundus reference images from optical coherence tomography</article-title><source>Comput Med Imaging Graph</source><year>2014</year><volume>38</volume><issue>5</issue><fpage>381</fpage><lpage>389</lpage><pub-id pub-id-type="pmid">24631317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compmedimag.2014.02.003</pub-id></element-citation><mixed-citation id="mc-CR25" publication-type="journal">Guimar&#227;es P, Rodrigues P, Lobo C, Leal S, Figueira J, Serranho P, et al. Ocular fundus reference images from optical coherence tomography. Comput Med Imaging Graph. 2014;38(5):381&#8211;9.<pub-id pub-id-type="pmid">24631317</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.compmedimag.2014.02.003</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>H</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>PI</given-names></name><name name-style="western"><surname>Ambr&#243;sio</surname><given-names>AF</given-names></name><name name-style="western"><surname>Castelo-Branco</surname><given-names>M</given-names></name><name name-style="western"><surname>Serranho</surname><given-names>P</given-names></name><etal/></person-group><article-title>Longitudinal normative OCT retinal thickness data for wild-type mice, and characterization of changes in the 3&#215;Tg-AD mice model of Alzheimer&#8217;s disease</article-title><source>Aging (Albany NY)</source><year>2021</year><volume>13</volume><issue>7</issue><fpage>9433</fpage><lpage>9454</lpage><pub-id pub-id-type="pmid">33799308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.202916</pub-id><pub-id pub-id-type="pmcid">PMC8064224</pub-id></element-citation><mixed-citation id="mc-CR26" publication-type="journal">Ferreira H, Martins J, Moreira PI, Ambr&#243;sio AF, Castelo-Branco M, Serranho P, et al. Longitudinal normative OCT retinal thickness data for wild-type mice, and characterization of changes in the 3&#215;Tg-AD mice model of Alzheimer&#8217;s disease. Aging (Albany NY). 2021;13(7):9433&#8211;54.<pub-id pub-id-type="pmid">33799308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.202916</pub-id><pub-id pub-id-type="pmcid">PMC8064224</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bernardes</surname><given-names>R</given-names></name></person-group><article-title>Optical coherence tomography: health information embedded on OCT signal statistics</article-title><source>Annu Int Conf IEEE Eng Med Biol Soc</source><year>2011</year><volume>2011</volume><fpage>6131</fpage><lpage>6133</lpage><pub-id pub-id-type="pmid">22255738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/IEMBS.2011.6091514</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Bernardes R. Optical coherence tomography: health information embedded on OCT signal statistics. Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:6131&#8211;3.<pub-id pub-id-type="pmid">22255738</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/IEMBS.2011.6091514</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>P</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>P</given-names></name><name name-style="western"><surname>Santos</surname><given-names>T</given-names></name><name name-style="western"><surname>Sim&#227;o</surname><given-names>S</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>T</given-names></name><name name-style="western"><surname>Serranho</surname><given-names>P</given-names></name><etal/></person-group><article-title>Two-dimensional segmentation of the retinal vascular network from optical coherence tomography</article-title><source>J Biomed Opt</source><year>2013</year><volume>18</volume><issue>12</issue><fpage>126011</fpage><pub-id pub-id-type="pmid">24343442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1117/1.JBO.18.12.126011</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">Rodrigues P, Guimar&#227;es P, Santos T, Sim&#227;o S, Miranda T, Serranho P, et al. Two-dimensional segmentation of the retinal vascular network from optical coherence tomography. J Biomed Opt. 2013;18(12):126011.<pub-id pub-id-type="pmid">24343442</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1117/1.JBO.18.12.126011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>M</given-names></name><name name-style="western"><surname>Araujo</surname><given-names>A</given-names></name><name name-style="western"><surname>Barbeiro</surname><given-names>S</given-names></name><name name-style="western"><surname>Caramelo</surname><given-names>F</given-names></name><name name-style="western"><surname>Correia</surname><given-names>A</given-names></name><name name-style="western"><surname>Marques</surname><given-names>MI</given-names></name><etal/></person-group><article-title>Simulation of cellular changes on optical coherence tomography of human retina</article-title><source>Annu Int Conf IEEE Eng Med Biol Soc</source><year>2015</year><volume>2015</volume><fpage>8147</fpage><lpage>8150</lpage><pub-id pub-id-type="pmid">26738185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/EMBC.2015.7320285</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Santos M, Araujo A, Barbeiro S, Caramelo F, Correia A, Marques MI, et al. Simulation of cellular changes on optical coherence tomography of human retina. Annu Int Conf IEEE Eng Med Biol Soc. 2015;2015:8147&#8211;50.<pub-id pub-id-type="pmid">26738185</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1109/EMBC.2015.7320285</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>H</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>A</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>PI</given-names></name><name name-style="western"><surname>Castelo-Branco</surname><given-names>M</given-names></name><name name-style="western"><surname>Ambr&#243;sio</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Characterization of the retinal changes of the 3&#215;Tg-AD mouse model of Alzheimer&#8217;s disease</article-title><source>Health Technol (Berl)</source><year>2020</year><volume>10</volume><issue>4</issue><fpage>875</fpage><lpage>883</lpage></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Ferreira H, Martins J, Nunes A, Moreira PI, Castelo-Branco M, Ambr&#243;sio AF, et al. Characterization of the retinal changes of the 3&#215;Tg-AD mouse model of Alzheimer&#8217;s disease. Health Technol (Berl). 2020;10(4):875&#8211;83.</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nunes</surname><given-names>A</given-names></name><name name-style="western"><surname>Silva</surname><given-names>G</given-names></name><name name-style="western"><surname>Duque</surname><given-names>C</given-names></name><name name-style="western"><surname>Janu&#225;rio</surname><given-names>C</given-names></name><name name-style="western"><surname>Santana</surname><given-names>I</given-names></name><name name-style="western"><surname>Ambr&#243;sio</surname><given-names>AF</given-names></name><etal/></person-group><article-title>Retinal texture biomarkers may help to discriminate between Alzheimer&#8217;s, Parkinson&#8217;s, and healthy controls</article-title><source>PLoS ONE</source><year>2019</year><volume>14</volume><issue>6</issue><fpage>e0218826</fpage><pub-id pub-id-type="pmid">31226150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0218826</pub-id><pub-id pub-id-type="pmcid">PMC6588252</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Nunes A, Silva G, Duque C, Janu&#225;rio C, Santana I, Ambr&#243;sio AF, et al. Retinal texture biomarkers may help to discriminate between Alzheimer&#8217;s, Parkinson&#8217;s, and healthy controls. PLoS One. 2019;14(6):e0218826.<pub-id pub-id-type="pmid">31226150</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0218826</pub-id><pub-id pub-id-type="pmcid">PMC6588252</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>S</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>P</given-names></name><name name-style="western"><surname>Campos</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Fernandes</surname><given-names>R</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J</given-names></name><name name-style="western"><surname>Castelo-Branco</surname><given-names>M</given-names></name><etal/></person-group><article-title>Retinal OCT-derived texture features as potential biomarkers for early diagnosis and progression of diabetic retinopathy</article-title><source>Invest Ophthalmol Vis Sci</source><year>2025</year><volume>66</volume><issue>1</issue><fpage>7</fpage><pub-id pub-id-type="pmid">39760689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.66.1.7</pub-id><pub-id pub-id-type="pmcid">PMC11717131</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Oliveira S, Guimar&#227;es P, Campos EJ, Fernandes R, Martins J, Castelo-Branco M, et al. Retinal OCT-derived texture features as potential biomarkers for early diagnosis and progression of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2025;66(1):7.<pub-id pub-id-type="pmid">39760689</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.66.1.7</pub-id><pub-id pub-id-type="pmcid">PMC11717131</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kowluru</surname><given-names>RA</given-names></name></person-group><article-title>Retinopathy in a diet-induced type 2 diabetic rat model and role of epigenetic modifications</article-title><source>Diabetes</source><year>2020</year><volume>69</volume><issue>4</issue><fpage>689</fpage><lpage>698</lpage><pub-id pub-id-type="pmid">31949005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db19-1009</pub-id><pub-id pub-id-type="pmcid">PMC7085254</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Kowluru RA. Retinopathy in a diet-induced type 2 diabetic rat model and role of epigenetic modifications. Diabetes. 2020;69(4):689&#8211;98.<pub-id pub-id-type="pmid">31949005</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db19-1009</pub-id><pub-id pub-id-type="pmcid">PMC7085254</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barri&#232;re</surname><given-names>DA</given-names></name><name name-style="western"><surname>Noll</surname><given-names>C</given-names></name><name name-style="western"><surname>Roussy</surname><given-names>G</given-names></name><name name-style="western"><surname>Lizotte</surname><given-names>F</given-names></name><name name-style="western"><surname>Kessai</surname><given-names>A</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>K</given-names></name><etal/></person-group><article-title>Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications</article-title><source>Sci Rep</source><year>2018</year><volume>8</volume><issue>1</issue><fpage>424</fpage><pub-id pub-id-type="pmid">29323186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-18896-5</pub-id><pub-id pub-id-type="pmcid">PMC5765114</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Barri&#232;re DA, Noll C, Roussy G, Lizotte F, Kessai A, Kirby K, et al. Combination of high-fat/high-fructose diet and low-dose streptozotocin to model long-term type-2 diabetes complications. Sci Rep. 2018;8(1):424.<pub-id pub-id-type="pmid">29323186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-017-18896-5</pub-id><pub-id pub-id-type="pmcid">PMC5765114</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarkson-Townsend</surname><given-names>DA</given-names></name><name name-style="western"><surname>Douglass</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Singh</surname><given-names>A</given-names></name><name name-style="western"><surname>Allen</surname><given-names>RS</given-names></name><name name-style="western"><surname>Uwaifo</surname><given-names>IN</given-names></name><name name-style="western"><surname>Pardue</surname><given-names>MT</given-names></name></person-group><article-title>Impacts of high fat diet on ocular outcomes in rodent models of visual disease</article-title><source>Exp Eye Res</source><year>2021</year><volume>204</volume><fpage>108440</fpage><pub-id pub-id-type="pmid">33444582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exer.2021.108440</pub-id><pub-id pub-id-type="pmcid">PMC7946735</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Clarkson-Townsend DA, Douglass AJ, Singh A, Allen RS, Uwaifo IN, Pardue MT. Impacts of high fat diet on ocular outcomes in rodent models of visual disease. Exp Eye Res. 2021;204:108440.<pub-id pub-id-type="pmid">33444582</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.exer.2021.108440</pub-id><pub-id pub-id-type="pmcid">PMC7946735</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batista</surname><given-names>A</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>P</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>PI</given-names></name><name name-style="western"><surname>Ambr&#243;sio</surname><given-names>AF</given-names></name><name name-style="western"><surname>Castelo-Branco</surname><given-names>M</given-names></name><etal/></person-group><article-title>Normative mice retinal thickness: 16-month longitudinal characterization of wild-type mice and changes in a model of Alzheimer&#8217;s disease</article-title><source>Front Aging Neurosci</source><year>2023</year><volume>15</volume><fpage>1161847</fpage><pub-id pub-id-type="pmid">37091517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1161847</pub-id><pub-id pub-id-type="pmcid">PMC10117679</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Batista A, Guimar&#227;es P, Martins J, Moreira PI, Ambr&#243;sio AF, Castelo-Branco M, et al. Normative mice retinal thickness: 16-month longitudinal characterization of wild-type mice and changes in a model of Alzheimer&#8217;s disease. Front Aging Neurosci. 2023;15:1161847.<pub-id pub-id-type="pmid">37091517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fnagi.2023.1161847</pub-id><pub-id pub-id-type="pmcid">PMC10117679</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Batista</surname><given-names>A</given-names></name><name name-style="western"><surname>Guimar&#227;es</surname><given-names>P</given-names></name><name name-style="western"><surname>Serranho</surname><given-names>P</given-names></name><name name-style="western"><surname>Nunes</surname><given-names>A</given-names></name><name name-style="western"><surname>Martins</surname><given-names>J</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>PI</given-names></name><etal/></person-group><article-title>Retinal imaging in animal models: searching for biomarkers of neurodegeneration</article-title><source>Front Ophthalmol (Lausanne)</source><year>2023</year><volume>3</volume><fpage>1156605</fpage><pub-id pub-id-type="pmid">38983000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fopht.2023.1156605</pub-id><pub-id pub-id-type="pmcid">PMC11182266</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Batista A, Guimar&#227;es P, Serranho P, Nunes A, Martins J, Moreira PI, et al. Retinal imaging in animal models: searching for biomarkers of neurodegeneration. Front Ophthalmol (Lausanne). 2023;3:1156605.<pub-id pub-id-type="pmid">38983000</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fopht.2023.1156605</pub-id><pub-id pub-id-type="pmcid">PMC11182266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haralick</surname><given-names>RM</given-names></name><name name-style="western"><surname>Shanmugam</surname><given-names>K</given-names></name><name name-style="western"><surname>Dinstein</surname><given-names>I</given-names></name></person-group><article-title>Textural features for image classification</article-title><source>IEEE Trans Syst Man Cybern.</source><year>1973</year><volume>SMC-3</volume><issue>6</issue><fpage>610</fpage><lpage>621</lpage></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Haralick RM, Shanmugam K, Dinstein I. Textural features for image classification. IEEE Trans Syst Man Cybern. 1973;SMC-3(6):610&#8211;21.</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haralick</surname><given-names>RM</given-names></name></person-group><article-title>Statistical and structural approaches to texture</article-title><source>Proc IEEE</source><year>1979</year><volume>67</volume><issue>5</issue><fpage>786</fpage><lpage>804</lpage></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Haralick RM. Statistical and structural approaches to texture. Proc IEEE. 1979;67(5):786&#8211;804.</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Conners</surname><given-names>RW</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>MM</given-names></name><name name-style="western"><surname>Harlow</surname><given-names>CA</given-names></name></person-group><article-title>Segmentation of a high-resolution urban scene using texture operators</article-title><source>Comput Vis Graph Image Process</source><year>1984</year><volume>25</volume><issue>3</issue><fpage>273</fpage><lpage>310</lpage></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Conners RW, Trivedi MM, Harlow CA. Segmentation of a high-resolution urban scene using texture operators. Comput Vis Graph Image Process. 1984;25(3):273&#8211;310. 10.1016/0734-189X(84)90197-X.</mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clausi</surname><given-names>DA</given-names></name></person-group><article-title>An analysis of co-occurrence texture statistics as a function of grey level quantization</article-title><source>Can J Remote Sens</source><year>2002</year><volume>28</volume><issue>1</issue><fpage>45</fpage><lpage>62</lpage></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Clausi DA. An analysis of co-occurrence texture statistics as a function of grey level quantization. Can J Remote Sens. 2002;28(1):45&#8211;62. 10.5589/m02-004.</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Soh</surname><given-names>LK</given-names></name><name name-style="western"><surname>Tsatsoulis</surname><given-names>C</given-names></name></person-group><article-title>Texture analysis of SAR sea ice imagery using gray level co-occurrence matrices</article-title><source>IEEE Trans Geosci Remote Sens</source><year>1999</year><volume>37</volume><issue>2</issue><fpage>780</fpage><lpage>795</lpage></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Soh LK, Tsatsoulis C. Texture analysis of SAR sea ice imagery using gray level co-occurrence matrices. IEEE Trans Geosci Remote Sens. 1999;37(2):780&#8211;95.</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lachin</surname><given-names>JM</given-names></name><name name-style="western"><surname>Genuth</surname><given-names>S</given-names></name><name name-style="western"><surname>Nathan</surname><given-names>DM</given-names></name><name name-style="western"><surname>Zinman</surname><given-names>B</given-names></name><name name-style="western"><surname>Rutledge</surname><given-names>BN</given-names></name></person-group><article-title>Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial&#8211;revisited</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><issue>4</issue><fpage>995</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">18223010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db07-1618</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Lachin JM, Genuth S, Nathan DM, Zinman B, Rutledge BN. Effect of glycemic exposure on the risk of microvascular complications in the diabetes control and complications trial&#8211;revisited. Diabetes. 2008;57(4):995&#8211;1001.<pub-id pub-id-type="pmid">18223010</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2337/db07-1618</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carpineto</surname><given-names>P</given-names></name><name name-style="western"><surname>Toto</surname><given-names>L</given-names></name><name name-style="western"><surname>Aloia</surname><given-names>R</given-names></name><name name-style="western"><surname>Ciciarelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Borrelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Vitacolonna</surname><given-names>E</given-names></name><etal/></person-group><article-title>Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus</article-title><source>Eye (Lond)</source><year>2016</year><volume>30</volume><issue>5</issue><fpage>673</fpage><lpage>679</lpage><pub-id pub-id-type="pmid">26869156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/eye.2016.13</pub-id><pub-id pub-id-type="pmcid">PMC4869127</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Carpineto P, Toto L, Aloia R, Ciciarelli V, Borrelli E, Vitacolonna E, et al. Neuroretinal alterations in the early stages of diabetic retinopathy in patients with type 2 diabetes mellitus. Eye (Lond). 2016;30(5):673&#8211;9.<pub-id pub-id-type="pmid">26869156</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/eye.2016.13</pub-id><pub-id pub-id-type="pmcid">PMC4869127</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sung</surname><given-names>JY</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MW</given-names></name><name name-style="western"><surname>Lim</surname><given-names>HB</given-names></name><name name-style="western"><surname>Ryu</surname><given-names>CK</given-names></name><name name-style="western"><surname>Yu</surname><given-names>HY</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JY</given-names></name></person-group><article-title>The ganglion cell-inner plexiform layer thickness/vessel density of superficial vascular plexus ratio according to the progression of diabetic retinopathy</article-title><source>Invest Ophthalmol Vis Sci</source><year>2022</year><volume>63</volume><issue>6</issue><fpage>4</fpage><pub-id pub-id-type="pmid">35653120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.63.6.4</pub-id><pub-id pub-id-type="pmcid">PMC9172016</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Sung JY, Lee MW, Lim HB, Ryu CK, Yu HY, Kim JY. The ganglion cell-inner plexiform layer thickness/vessel density of superficial vascular plexus ratio according to the progression of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2022;63(6):4.<pub-id pub-id-type="pmid">35653120</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.63.6.4</pub-id><pub-id pub-id-type="pmcid">PMC9172016</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vujosevic</surname><given-names>S</given-names></name><name name-style="western"><surname>Midena</surname><given-names>E</given-names></name></person-group><article-title>Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and m&#252;ller cells alterations</article-title><source>J Diabetes Res</source><year>2013</year><volume>2013</volume><fpage>905058</fpage><pub-id pub-id-type="pmid">23841106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/905058</pub-id><pub-id pub-id-type="pmcid">PMC3694491</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Vujosevic S, Midena E. Retinal layers changes in human preclinical and early clinical diabetic retinopathy support early retinal neuronal and m&#252;ller cells alterations. J Diabetes Res. 2013;2013:905058.<pub-id pub-id-type="pmid">23841106</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2013/905058</pub-id><pub-id pub-id-type="pmcid">PMC3694491</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luu</surname><given-names>CD</given-names></name><name name-style="western"><surname>Szental</surname><given-names>JA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SY</given-names></name><name name-style="western"><surname>Lavanya</surname><given-names>R</given-names></name><name name-style="western"><surname>Wong</surname><given-names>TY</given-names></name></person-group><article-title>Correlation between retinal oscillatory potentials and retinal vascular caliber in type 2 diabetes</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><issue>1</issue><fpage>482</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">19710418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.09-4069</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Luu CD, Szental JA, Lee SY, Lavanya R, Wong TY. Correlation between retinal oscillatory potentials and retinal vascular caliber in type 2 diabetes. Invest Ophthalmol Vis Sci. 2010;51(1):482&#8211;6.<pub-id pub-id-type="pmid">19710418</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.09-4069</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>T&#259;nasie</surname><given-names>CA</given-names></name><name name-style="western"><surname>Dan</surname><given-names>AO</given-names></name><name name-style="western"><surname>Ic&#259;</surname><given-names>OM</given-names></name><name name-style="western"><surname>Mercu&#539;</surname><given-names>MF</given-names></name><name name-style="western"><surname>Mitroi</surname><given-names>G</given-names></name><name name-style="western"><surname>Taisescu</surname><given-names>CI</given-names></name><etal/></person-group><article-title>Retinal functional impairment in diabetic retinopathy</article-title><source>Biomedicines</source><year>2023</year><volume>12</volume><issue>1</issue><fpage>44</fpage><pub-id pub-id-type="pmid">38255151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12010044</pub-id><pub-id pub-id-type="pmcid">PMC10813090</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">T&#259;nasie CA, Dan AO, Ic&#259; OM, Mercu&#539; MF, Mitroi G, Taisescu CI, et al. Retinal functional impairment in diabetic retinopathy. Biomedicines. 2023;12(1):44.<pub-id pub-id-type="pmid">38255151</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/biomedicines12010044</pub-id><pub-id pub-id-type="pmcid">PMC10813090</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kizawa</surname><given-names>J</given-names></name><name name-style="western"><surname>Machida</surname><given-names>S</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Gotoh</surname><given-names>Y</given-names></name><name name-style="western"><surname>Kurosaka</surname><given-names>D</given-names></name></person-group><article-title>Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy</article-title><source>Jpn J Ophthalmol</source><year>2006</year><volume>50</volume><issue>4</issue><fpage>367</fpage><lpage>373</lpage><pub-id pub-id-type="pmid">16897223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10384-006-0326-0</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Kizawa J, Machida S, Kobayashi T, Gotoh Y, Kurosaka D. Changes of oscillatory potentials and photopic negative response in patients with early diabetic retinopathy. Jpn J Ophthalmol. 2006;50(4):367&#8211;73.<pub-id pub-id-type="pmid">16897223</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10384-006-0326-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sergeys</surname><given-names>J</given-names></name><name name-style="western"><surname>Etienne</surname><given-names>I</given-names></name><name name-style="western"><surname>Van Hove</surname><given-names>I</given-names></name><name name-style="western"><surname>Lefevere</surname><given-names>E</given-names></name><name name-style="western"><surname>Stalmans</surname><given-names>I</given-names></name><name name-style="western"><surname>Feyen</surname><given-names>JHM</given-names></name><etal/></person-group><article-title>Longitudinal in vivo characterization of the streptozotocin-induced diabetic mouse model: focus on early inner retinal responses</article-title><source>Invest Ophthalmol Vis Sci</source><year>2019</year><volume>60</volume><issue>2</issue><fpage>807</fpage><lpage>822</lpage><pub-id pub-id-type="pmid">30811545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.18-25372</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Sergeys J, Etienne I, Van Hove I, Lefevere E, Stalmans I, Feyen JHM, et al. Longitudinal in vivo characterization of the streptozotocin-induced diabetic mouse model: focus on early inner retinal responses. Invest Ophthalmol Vis Sci. 2019;60(2):807&#8211;22.<pub-id pub-id-type="pmid">30811545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/iovs.18-25372</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardue</surname><given-names>MT</given-names></name><name name-style="western"><surname>Barnes</surname><given-names>CS</given-names></name><name name-style="western"><surname>Kim</surname><given-names>MK</given-names></name><name name-style="western"><surname>Aung</surname><given-names>MH</given-names></name><name name-style="western"><surname>Amarnath</surname><given-names>R</given-names></name><name name-style="western"><surname>Olson</surname><given-names>DE</given-names></name><etal/></person-group><article-title>Rodent hyperglycemia-induced inner retinal deficits are mirrored in human diabetes</article-title><source>Transl Vis Sci Technol</source><year>2014</year><volume>3</volume><issue>3</issue><fpage>6</fpage><pub-id pub-id-type="pmid">24959388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/tvst.3.3.6</pub-id><pub-id pub-id-type="pmcid">PMC4064622</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Pardue MT, Barnes CS, Kim MK, Aung MH, Amarnath R, Olson DE, et al. Rodent hyperglycemia-induced inner retinal deficits are mirrored in human diabetes. Transl Vis Sci Technol. 2014;3(3):6.<pub-id pub-id-type="pmid">24959388</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1167/tvst.3.3.6</pub-id><pub-id pub-id-type="pmcid">PMC4064622</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Araiz</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Alv&#225;rez-N&#243;lting</surname><given-names>R</given-names></name><name name-style="western"><surname>Miranda</surname><given-names>M</given-names></name><name name-style="western"><surname>Genoves</surname><given-names>JM</given-names></name><name name-style="western"><surname>Arnal</surname><given-names>E</given-names></name><name name-style="western"><surname>Bosch-Morell</surname><given-names>F</given-names></name><etal/></person-group><article-title>Changes in the ERG of STZ induced diabetic rats and its utility to detect other cerebral alterations</article-title><source>Invest Ophthalmol Vis Sci</source><year>2010</year><volume>51</volume><issue>13</issue><fpage>2464</fpage></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Araiz JJ, Alv&#225;rez-N&#243;lting R, Miranda M, Genoves JM, Arnal E, Bosch-Morell F, et al. Changes in the ERG of STZ induced diabetic rats and its utility to detect other cerebral alterations. Invest Ophthalmol Vis Sci. 2010;51(13):2464.</mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunha-Vaz</surname><given-names>JG</given-names></name></person-group><article-title>Pathophysiology of diabetic retinopathy</article-title><source>Br J Ophthalmol</source><year>1978</year><volume>62</volume><issue>6</issue><fpage>351</fpage><lpage>355</lpage><pub-id pub-id-type="pmid">666982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjo.62.6.351</pub-id><pub-id pub-id-type="pmcid">PMC1043233</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Cunha-Vaz JG. Pathophysiology of diabetic retinopathy. Br J Ophthalmol. 1978;62(6):351&#8211;5.<pub-id pub-id-type="pmid">666982</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bjo.62.6.351</pub-id><pub-id pub-id-type="pmcid">PMC1043233</pub-id></mixed-citation></citation-alternatives></ref></ref-list></back></article>
        
    </metadata>
</record>
    </GetRecord>

</OAI-PMH>